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ABSTRACT
Introduction: Hemangiomas are the most common benign tumor of infancy.1 They are
unique in that their behavioral course is well-described with a microvascular proliferative
phase, quiescent phase and regressive fatty involuting phase.2-4 First, it is posited in this
work that the cell of origin will have angiogenic and adipogenic properties, like the
pericyte.5 Second, the predilection of the lesion to areas of embryologic fusions in the head
and neck6-9 indicate that the neural crest may be involved. Previous research focused on the
angiogenic characteristics of proliferating hemangiomas, this work is novel in that it
investigates markers involved in adipogenesis. This study explores the possibility that
hemangiomas are pericyte-like stem cell tumors, derived from the neural crest, capable of
adipocyte differentiation.
Methods: Markers for pericytes, stem cells and neural crest cells as well as adipocyte
differentiation were analyzed using using immunohistochemistry, immunofluorescence
and quantitative RT-PCR. These markers included: NG2, SMA, calponin, CD90(Thy1),
GLUT1, dlk (pericytes); Pauf5 (Oct4), Nanog, Sox2, Sox9, Sox10, c-myc (stem cells);
Nestin, Sox10, NGFR (p75), NG2 (neural crest cells) and C/EBPα, C/EBPβ, C/EBPδ,
PPARγ, dlk, RXR, SREBF, Sox9, and Krϋppel-like factors (KLF2, KLF4, KLF5, KLF6,
KLF15) (adipocyte differentiation markers). Immunohistochemistry and
immunofluorescence was done on formalin-fixed, paraffin-embedded archival tissue.
qRT-PCR was performed on 15 hemangioma specimens (5 proliferating, 3 early
quiescent, 4 late quiescent, and 5 involuting) and compared to Human Dermal
Microvascular Endothlial Cells (HDMEC) utilizing the ∆∆Ct method of analysis.
Hemangioma phase was determined by clinical notes. To compare hemangioma phases,
a one-way ANOVA was done with a Tukey HSD post hoc analysis.
Results: Immunohistochemistry identified these markers in the periluminal structures
within the hemangiomas: GLUT1, dlk, SMA, and Nestin. Immunofluorescence
identified these markers in a confirmatory pattern: GLUT1, dlk, SMA, Nestin, Sox2,
Calponin and NG2. The qRTPCR analysis revealed that the relative expression of all
(pericyte, stem cell, neural crest and adipocyte differentiation) analyzed markers was
greater than that of the HDMEC control. Significant differences were found between the
hemangioma phases for Sox9, C/EBPβ and KLF2
Conclusion: The work presented in this thesis is novel and informative. It demonstrated
that hemangiomas indeed express pericyte, stem cell and neural crest cell markers. This
is the first study to identify factors involved in adipocyte differentiation including dlk,
PPARγ and KLFs. The complex adipogenesis transcription cascade complicates the
ability to draw conclusion in regard to adipocyte differentiation. However, the data
presented provides support for the theory that hemangiomas are pericyte-like stem cell
tumors derived from the neural crest capable of adipocyte differentiation
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OVERVIEW
Hemangiomas are the most common benign tumor of infancy1 and yet optimal
treatment and their pathogenesis remain unknown. They are unique among tumors in that
their behavioral course is well-described with a proliferative, quiescent and involuting
phase.2-4 However, the different phases progress with extremely variable times of
duration from patient to patient. In general, the lesion appears within the first days to
weeks of birth as a pale, blue-ish patch.3 This patch, although not always observed,
transforms into a red-pink papule of microvascular components which proliferate and
grow disproportionately compared to the infant’s growth, Figure 1a.
Hemangiomas vary from vascular malformations in that they are present at birth
and grow proportionately with the child. On histology, diagnosis can be made with a
high degree of confidence on the basis of strong immunoreactivity with antibodies
against the glucose transporter protein isoform 1 (GLUT1).10-13 This can assist in the
differentiation between normal vasculature of the skin, vascular malformations, and other
benign vascular tumors (pygonic granuloma, tufted angioma and kaposiform
hemangiomendothelioma).13
Most (~80%) of lesions have a benign course8, 14 but common complications
during the proliferative phase include ulceration, bleeding and pain.15, 16 Depending on
the location and size of the lesion, visual development and airway can be
compromised.16-18 The proliferative phase lasts arguably from 2 weeks to 1 year. To
date, there is no way to predict how long a lesion will grow, how large a lesion will
become or the complications that may ensue..
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Figure 1: Presentation of common hemangioma

(a)

(b)

Here is an example of a common (a) proliferating/early quiescent hemangioma in an
infant. The lesion is bright red and well-circumcised, no ulceration or functional
impairment resulted from the clinical course. The next panel (b) shows the same patient
with the lesion in the late quiescent/involuting phase one year later. The fibrofatty
residuum can be seen characterized by a change in the color from red to a skin-colored
tone as well as a decrease in the size.

After the proliferative phase, the lesion enters a quiescent phase. During this
phase, little change is seen within the clinical milieu of the lesion. There is no further
growth or change in color and the incidence of complications related to bleeding or
function are, again, related to location and size. The quiescent phase is variable in
duration, lasting from weeks to years. The final phase is the involuting phase. The lesion
begins to shrink and the color regresses from the red-pink vascular color to a skin-tone or
scar appropriate to the patient, Figure 1b.7, 19-21 Some lesions will completely regress and
leave no visible residuum while others will be left with a fibrofatty scar.22 It is
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commonly quoted that 30% of lesions will involute by age 3, 50% by age 5 and 80% by
age 8.22, 23
Obvious outliers exist in the patient population but overall, most hemangiomas
present and progress in the outlined manner. Other distinctive characteristics of
hemangiomas are in whom and where they present. Hemangiomas occur more
commonly in female infants15, 16, 24-28 of Caucasian and white-Hispanic descent.26, 27
They are also more common in premature infants.8, 28, 29 The distribution of lesions is
predominantly in the head and neck region, though lesions occur throughout the body.6-9
For a full review of the literature concerning epidemiology of hemangiomas see
Supplement Text.
Each of these unique elements have lent to physician speculation on the origin of
hemangiomas. Most previous research and treatments focus on the proliferative elements
including vascular endothelial cells and factors influencing angiogenesis and
vasculogenesis such as basic fibroblast growth factor (bFGF), vascular endothelial
growth factor (VEGF) and matrix metallopeptidase-9 (MMP-9). Given the relation of the
lesion’s appearance to labor and delivery, there is conjecture surrounding changing
estrogen levels and hypoxic events including the influence of hypoxia-induced factor-1α
(HIF-1α). Hypothesises posited include: a viral etiology, placental emboli material,
endothelial progenitor cells, genetic abnormalities, developmental field defects as well as
angiogenic, hormonal, and hypoxia-induced growth factors. For a full review of the
literature regarding these hypotheses and growth factors see Supplement Text.
Current medical treatments target angiogenesis and include certain chemotherapy
agents (interferon α, cyclophsophamide and vincristine) as well as corticosteroids.
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Propranolol, recently introduced, displays a remarkable ability to shrink proliferative
lesions, although the exact mechanism of action is still unknown. Nonetheless, medical
treatments can be inadequate for complicated lesions leading to indications for surgical
excision and use of laser treatments. For a full review of the treatment modalities see
Supplement Text.
SPECIFIC AIMS
Taking the unique behavioral and clinical characteristics together, we formulated
an alternative hypothesis to those already in practice. The theory investigated in this
work is that hemangiomas are pericyte-like stem cell tumors, derived from the neural
crest, capable of adipocyte differentiation. This will be accomplished using
immunohistochemistry, immunofluorscence and qRT-PCR to identify related cell
markers. The implications of this hypothesis may create better prognostic markers and
new therapeutic targets such as proadipogenic factors. A summary of the hypothesis is
illustrated in Figure 2.
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Figure 2: Overview of Hypothesis.
(a) Cranial neural crest cells differentiate into the the same cells in the head and neck
region as mesenchymal stem cells do elsewhere, including pericytes and vascular
smooth muscle cells.
(b) Pericytes play an active role in (1) primitive formation of blood vessels during
vasculogenesis, (2) organized angiogenesis and (3) adipogenesis in established
adipocyte tissue.
(c) Proliferating hemangiomas involve formation of unorganized microvascular
components which during the involuting phase organize into mature blood vessels
accompanied by fibrofatty tissue development. Adapted from Kahn Science
2008.42 CREDIT: P. HUEY
Embryologic Stem Cell
Neural Crest Stem Cell

Osteoblast

Chondroblast

Vasculogenesis
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Hemangioma

Mesenchymal Stem Cell
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Angiogenesis
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Aim 1:

Demonstrate hemangiomas bear lineage markers of pericytes
Neural glial protein 2 (NG2), smooth muscle actin (SMA), calponin,
CD90 (Thy-1), GLUT1 and Delta-like kinase (dlk, aka Pref-1)

Given the microvascular and the fatty component of hemangioma progression, our theory
posits that hemangiomas originate from a cell entity capable of differentiating into both
microvascular and fatty cell types.
. Pericytes are perivascular cells surrounding microvessels such as arterioles,
capillaries, and venules.30-33 They play an active part in developmental and regulation of
angiogenic processes.34 Similar to multipotent mesenchymal stem cells, pericytes have
been shown to differentiate into chondrocytes, osteocytes, and adipocytes.35, 36 The
pericyte has stem cell-like properties because it is capable of differentiation into
microvascular components during vasculogenesis and angiogenesis and adipocytes. A
landmark study by Tang et al. provides reasonable evidence that, in mice, the pericyte is
the precursor cell within adipocyte tissue that forms new adipocyte cells.5, 37
Pericytes have been isolated from skeletal muscle, pancreas, adipose tissue, brain
and placenta using CD146, PDGFR-β, and NG2 expression in the absence of
hematopoietic, endothelial, and myogenic markers.38, 39 Juvenile pericytes are reported to
express smooth muscle cell markers such as calponin and SMA as well as NG2 in the
absence of mature smooth muscle cell marker such as SM22-α and SMMHC.40 GLUT1
and dlk are also markers demonstrated in pericytes.39, 41 To date, there is no known
marker exclusively restricted to pericytes.
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Aim 2:

Demonstrate hemangiomas bear lineage markers of stem cells
Pauf5 (Oct4), Nanog, Sox2, Sox9, Sox10, c-myc

If indeed hemangiomas originate from a pluripotent cell type, they should demonstrate
stem cell markers. Previous work identified mesenchymal stem cells in hemangioma
tissue which were at the highest concentration during the proliferative phase.43 These
cells have the potential for clonal proliferation as well as for multi-lineage differentiation
including adipocyte, osteoblast, chondrocyte, myocyte, neuronal cell and hepatocyte.44, 45
Additionally, these hemangioma cells were more similar to stem cells than endothelial
cells as the isolated cells express surface markers SH2(CD105), SH3, SH4, CD90 (Thy1), CD29, SMA, VEGFR-1/Flt-1, neurolipin, and CD133 but not hematopoietic markers:
CD45 and CD14 or endothelial markers: CD34 and CD31.43, 45 CD90 (Thy-1) a
mesenchymal stem cell marker, was the gene most differentially up-regulated in
proliferating compared with involuting phase hemangiomas in a micro-array analysis.46
Isolated hemangioma cells when injected subcutaneously in the back of
immunodeficient mice organized into functional GLUT1+ and CD31+ vessels within 14
days of implantation.13, 47 Two months after implantation the vessels diminished and
human adipocytes became evident. Furthermore, GFP-labeled hemangioma stem cells in
vivo were shown to form adipocytes in addition to the endothelial lining of the vessels
indicating that the implanted cells were not murine-derivied.47 This supports the concept
that there is innate programming in the hemangioma stem cell for both its proliferative
and involutive characteristics.
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When analyzing hemangioma endothelial cells, the differentiated cells exhibit an
expression profile and behavior much closer to that of fetal endothelial cells compared to
adult endothelial cells. This suggests that hemangioma cells are not fully differentiated
or they maintain a degree of pluripotency.47-52
A host of stem cell markers exist in an elegant and complicated regulatory
transcription cascade for a differentiation pathway yet to be completely understood. This
study includes a small subset of these markers: Sox2, Nanog, Pauf5 (Oct4), Sox9, NGFR
(p75), NG2, and Nestin. Previous work by this laboratory analyzed these markers: cmyc, Sox2, Nanog, Pauf5, Nestin, NG2, Sox10 and CD90(Thy-1). Each of these markers
had a qRT-PCR relative expression greater than the control endothelial cells. Markers
were included based on their potential overlap in other cell types, such as pericytes and
neural crest cells, as well as biologic processes, such as adipogenesis.
Aim 3:

Demonstrate hemangiomas bear lineage markers of neural crest cells
Nestin, Sox10, NGFR (neurotrophin factor receptor aka p75), NG2

Most hemangiomas occur in the head and neck. This leads to the postulation that
hemangiomas are derived from a cell-line found predominantly in the head and neck,
such as neural crest cells. Not only are neural crest cells found predominately in the head
and neck, but they are also considered to be a stem cell line. Of interest, multiple lines of
cells (pericytes, adipocytes, myocytes and osteoblasts) that are thought to be of
mesoderm origin appear to be derived from the neural crest in the head and neck
region.53-55 Specifically of importance in hemangiomas, head and neck blood vessel
pericytes and smooth muscle cells are derived from the neural crest.56
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In addition to most lesions being located in the craniofacial region, there appears
to be a pattern in regards to the location within the head and neck. Waner et al., when
reviewing hemangioma distribution in the head and neck region, observed that lesions
appear in defined regions such as the sites of embryonic fusion.6 The distribution
observed is demonstrated in Figure 3. Interestingly, these are sites of neural crest cell
migration which follow a predictable and non-random pathway with precise targets in the
head and brachial arches.57
Figure 3: Distribution of hemangiomas in the head and neck region
Waner et al. presented a review of the
distribution of hemangiomas in the head and
neck region. The focal sites of hemangioma
occurrence are superimposed on the
embryological fusion plates.6

Failure of proper neural crest migration
leads to significant morphological abnormalities of the face, neck and cardiovascular
system.58, 59 The constellation of symptoms associated with PHACE syndrome (posterior
fossa anomalies, hemangioma, arterial lesions, cardiac abnormalities/aortic coarctation,
and abnormalities of the eye60) are proven to be caused by neural crest defects, with the
exception of hemangiomas. The hemangioma involved in PHACE syndrome is typically
larger, termed “segmental” hemangiomas. An example of the distribution of this larger
hemangioma subtype is illustrated in Figure 4. By association, hemangiomas may also
be a result from a neural crest defect.
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Figure 4: Segmental hemangioma distribution
Haggstrom et al. analyzed the characteristics of large
segmental hemangiomas.61 This is the pattern of
distribution found. As shown, the segmental
hemangiomas tend to follow the distribution of the
trigeminal nerve, indicating that there are neural
derivatives involved in the origin of hemangiomas.
The “beard distribution” is similar to the Segment 3.
•
•
•
•

Segment 1 (frontotemporal)
Segment 2 (maxillary)
Segment 3 (mandibular)
Segment 4 (frontonasal)

Nestin, NGFR, and Sox10 are markers for neural crest-stem cells.62, 63 Nestin, an
intermediate filament expressed in neuroepithelial stem cells is often expressed in multilineage progenitor cells.62 NGFR is associated with cell differentiation to glial and neural
cells possibly explaining distribution of large hemangiomas, termed segmental
hemangiomas, along the branches of the trigeminal nerve. Sox10 interacts with Pax3 to
activate Mitf expression. This is a well-associated motif with the ventral neural crest
mirgration as well as denominating cells destined for the head and neck.64, 65 Previous
work by this lab identified Nestin, Sox10 and NG2 in hemangioma tissue via qRT-PCR
and FACS analysis.
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Aim 4:

Demonstrate hemangiomas express adipocyte differentiation markers
CCAAT-enhancer-binding protein(C/EBP)α, C/EBPβ, C/EBPδ,
peroxisome proliferator-activated receptors (PPAR)γ, Delta-like kinase
(dlk aka Pref1), retinoid x receptor (RXR), sterol regulatory elementbinding transcription factor 1 (SREBF), Sox9, Krϋppel-like factors (KLFs)

It is interesting to question how a vascular lesion with microvascular proliferative
behavior stops growing and subsequently regresses into a fibrofatty scar. This suggests a
maturation pathway that converts the lesion into adipocyte-like tissue. Less time and
energy has been spent on this peculiar behavior. If indeed, the cell of origin of
hemangiomas is a pericyte-like or rather a preadipocyte-like cell then hemangiomas
should demonstrate markers of adipocyte differentiation.
To date, the exact details of the adipogenic differentiation transcription cascade
remains to be completely understood; however, it is understood that differentiation
involves a number of temporally regulated gene-expression events including known
transcription factors, chromatin remodeling, feedback loops, and a number of inhibitory
factors. The most well-known and studied transcription factors are the delta-like kinase
(dlk, aka Pref-1), peroxisome proliferator-activated receptors (PPARs) and the CCAATenhancer-binding proteins (C/EBPs). More recently, the Krϋppel-like Factors (KLFs)
have been implicated in the regulatory cascade of adipogenesis.
Dlk is the major inhibitory molecule of adipogenesis in concert with Sox9. As
dlk and Sox9 levels decrease, C/EBPβ and δ rise transiently followed by the expression
of PPARγ within a positive feedback loop with C/EBPα. These temporally expressed
factors ensure commitment and transcription of adipocyte-specific genes that contribute
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to the necessary machinery for mature adipocyte function. Certain KLFs positively
(KLF4, KLF5, KLF6, and KLF 15) and negatively (KLF2) regulate the aforementioned
proteins. These are the transcription factors that will be of focus in this work. A
summary is offered in Figure 5, but for a more detailed review of adipogenesis and KLFs
see Supplement Text.
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Figure 5: Complex transcriptional cascade for adipocyte differentiation.
Summary image of transcriptional cascade involved in adipocyte differentiation beginning with preadipocytes/pericytes and ending
with a mature adipocyte. Adipocyte specific genes include those proteins necessary for sequestration, production and modification of
lipid and lipid byproducts. If hemangiomas have a default adipocyte differentiation target, they should express adipocyte
differentiation markers.

Adapted from Nagai et al.66
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METHODS
Immunohistochemistry Staining
Immunohistochemical analyses were performed using formalin-fixed, paraffinembedded archival tissue. Staining was performed on 5µm sections. The sections were
deparaffinized with xylene for 20 minutes and rehydrated through graded ethanol
solutions. To quench endogenous peroxidases, the slides were incubated with 3% H²O²,
dual endogenous enzyme block (S2003, Dako, Tokyo, Japan), for 5 minutes. Antibodybinding epitopes were retrieved using target retrieval solution (S1699, Dako, Tokyo,
Japan) (citrate buffer, pH 6). Then, the sections were incubated with GLUT1, SMA, dlk,
nestin, desmin, PDGFR-β, and p75 NGFR at dilution of 1:500, see Table 2 for details.
For detection, the sections were incubated for 10 minutes for the two steps in the labeled
streptovidin-biotin2 system, (K0675, Dako, Tokyo, Japan). The final step consisted of
Liquid DAB+ Substrate Chromagen System (K3468, Dako, Tokyo, Japan) for 10 minutes
followed by counterstaining with hematoxylin.
Solutions
Dual endogenous enzyme block (S2003, Dako, Tokyo, Japan
Target retrieval solution (10x) (S1699, Dako, Tokyo, Japan)
Labeled streptavidin-biotin2 system, horseradish peroxidase (LSAB2)
(K0675, Dako, Tokyo, Japan)
•

Biotin labeled affinity isolated goat anti-rabbit and goat anti-mouse
immunoglobulins in PBS, containgin stabilizing protein and 0.015 mol/L sodium
azide.

•

Streptavidin conjugated to horseradish peroxidase in PBS containing stabilizing
protein and anti-microbial agents

Liquid DAB+ Substrate Chromagen System (K3468, Dako, Tokyo, Japan)
•

3,3’-diaminobenzidine in chromage solution

•

Imidazole-HCl buffer, pH 7.5, containing hydrogen peroxidase and an antimicrobial agent

Immunofluorescence Staining
Paraffin embedded tissue samples were sampled for protein markers using
immunofluorescence analysis on unstained 5µm sections using species-specific
antibodies. All antibodies were diluted to a 1:100 concentration in 1%BSA/PBS
according to manufacturer recommendations. Species appropriate IgG-Alexa-Fluor 488
and 568nm, dilution 1:500, (Molecular Probes, Eugene, OR) secondary antibodies, with
subsequent 4',6-diamidino-2-phenylindole (DAPI) nuclear counterstaining were used.
Tissues were viewed with a Zeiss Axiovert 200M Fluorescence/Live cell Imaging
Microscope (Carl Zeiss Imaging Solutions, Thornwood, NY). Digital images were
acquired using the Zeiss LSM510 confocal computer system (Carl Zeiss Imaging
Solutions, Thornwood, NY).
The sections were deparaffinized with xylene for 20 minutes and rehydrated
through graded ethanol solutions. Antigen retrieval utilized heat mediated method with
the slide covered by 10mM citrate buffer at 95°C for 20 minutes. Slides were cooled to
room temperature for 20 minutes. They were washed with PBS-tween20 for 5 minutes,
twice. Serum blocking utilized normal goat serum blocking solution for 15 to 30
minutes, no wash required only removal of excess. Slides were incubated overnight with
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the primary antibody with a 1:100 dilution (diluted in 1% BSA in PBS; OR in Sigma
Antibody Diluent). Slides were then washed in PBS-tween20 for 5 minutes, twice and
followed with incubation with the secondary antibody, fluorophore labeled, for 30 minute
with a 1:500 dilution of appropriate fluorophore labeled secondary antibody to the
matching primary animal, such as Rabbit-anti-rat IgG (488, 568nm), H+L Ab (Invitrogen
10039) in PBS (no BSA added). After which, slides were washed in PBS-tween20 for 5
minutes, three times. Finally, DAPI cover slip solution was applied to slides and slides
were visualized under fluorescence microscope.
Solutions
Citrate Buffer (10mM Citric Acid, 0.05% Tween 20, pH 6.0)
Citric acid (anhydrous), 1.92 g
Distilled water, 1000 ml
Adjust pH to 6.0 with 1N NaOH and then add 0.5 ml of Tween 20 and mix well. Store
this solution at room temperature for 3 months or at 4 C for longer storage.
Normal Goat Serum Blocking Solution
5% goat serum (blocking)
1%BSA (stabilizer)
0.05% Tween 20 (detergent and surface tension reducer)
In 1X PBS, pH 7.2
Mix well and store at 4 ºC.
Washing Solution (1X PBS, 0.05% Tween 20, pH 7.2)
500ml 1X PBS
250ul tween 20
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Specimen Collection
All samples were collected in accordance with an approved HIC protocol
(#0507000430) as reviewed by the Yale University Medical School IRB. As these
samples were collected from children, fully informed parental consent and childhood
assent, when age appropriate, were obtained prior to surgery. Only the tissue remaining
following collection of the pathological specimen was used for this experiment.
Specimens for RNA extraction were separated into groups based on their clinical history,
presentation at the time of excision and pathology report as described below:
•

Proliferative: lesions with interval growth between the last two clinical visits
preceding surgery.

•

Early quiescent: lesions demonstrating no interval growth between the last two
clinic visits preceding surgery and less than 1.5 years of age.

•

Late quiescent: lesions demonstrating no interval growth between the last clinic
visits preceding surgery and greater than 1.5 years of age.

•

Involuted: demonstrated interval regression between the last two clinic visits
preceding surgery and were at least 3 years of age.

For comparison to normal microvascular endothelial cells, human dermal microvascular
endothelial cells (HDMEC) were used as the comparative controls.
Hemangioma tissue samples obtained at the time of excision were immediately
minced with straight razors into 1mm pieces and placed in 10mL Qiagen®RNA Later
(Qiagen) solution and flash frozen. Samples were stored at -80°C until isolation could be
performed.
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RNA Extraction
All implements were washed and treated with a RNAse Away(Molecular
BioProducts) wash and baked at 200°C to eradicate RNAse enzymes. Isolation was
completed on ice.
Using Manufacturer RNAzol®RT Protocol
RNA extraction was done according to RNAzol®RT manufacture protocol.
Briefly, tissue was immediately disrupted using a mortor and pestle and placed in chilled
RNAzol®RT. Cell cultures were lysed in the culture dish by removing culture medium,
adding RNAzol®RT and passed through a pipette to ensure full lysis. Water was added
and the samples were incubated at room temperature (15–25°C) for 15 minutes. Following
centrifugation at 12,000 g for 15 min, DNA, proteins and most polysaccharides form a
semisolid pellot with the RNA in the supernatant.
To precipitate the RNA, the RNA supernatant was transferred to a new tube and
equal parts of isopropranol were added to each sample. Samples were incubated at room
temperature for 10 minutes and centrifuged at 12,000 g for 10 minutes. The supernatant
was carefully removed and the remaining RNA pellet was washed twice with 75%
ethanol and centrifuged at 4,000 - 8,000 g for 3 minutes. Without drying, the RNA pellet
was dissolved in water to approach the RNA concentration of 1-2ug/mL. Total RNA
concentration and purity were analyzed by nanodrop spectrophotometry. Samples were
stored at -80°C until analysis.
Using Manufacturer QIAGEN® miRNeasy Mini Protocol
RNA from frozen tissue or culture samples was also obtained according to Qiaqen
miRNesay Mini protocol. Briefly, for frozen tissue samples, QIAzol Lysis
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Reagent®(Qiagen) was added directly to tissue and samples were homogenized using
TissueRuptor®(Qiagen). For cell culture, cells were trypsinized with 0.25% Trypsin
(1X) (Gibco: 15050-065) and cells were pelleted. To disrupt the cells, QIAzol Lysis
Reagent was added to the pellet followed by QIAshredder homogenizer (Qiagen).
The disrupted and homogenized samples were incubated at room temperature for
5 minutes. Chloroform was added to the samples and vortexed for 15 seconds. The
samples were incubated at room temperature for 3 minutes followed by centrifugation for
15 minutes at 12,000 x g at 4°C. After centrifugation, the sample separated into 3 phases:
an upper, colorless, aqueous phase containing RNA; a white interphase; and a lower, red,
organic phase. The upper aqueous phase was transferred to a new tube and 1.5 volumes
of 100% ethanol was added to the new tube.
To isolate the RNA, the solution and any precipitate was pipetted onto an RNeasy
Mini spin column in a 2 ml collection tube. The spin column was centrifugated at ≥8000
x g (≥10,000 rpm) for 15 seconds at room temperature. The flow-through was discarded.
Any remaining solution was placed onto the spin column and centrifugated. To wash the
column, Buffer RWT was added to the column and centrifugated for 15 seconds at ≥8000
x g (≥10,000 rpm). The flow-through was discarded. Next, two separate Buffer RPE
washes were performed with centrifugation for 15 seconds at ≥8000 x g (≥10,000 rpm) to
wash the column. The flow-through was discarded. The column was dried by
centrifuging the spin column for 2 minutes at ≥8000 x g (≥10,000 rpm). The spin column
was placed on a new 1.5 ml collection tube. Finally, 50 µl RNase-free water was pipetted
directly onto the RNeasy Mini spin column membrane and the spin column was
centrifugated for 1 minute at ≥8000 x g (≥10,000 rpm) to elute the RNA.
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Quantitative Real Time Polymerase Chain Reaction
One-step Taqman-based quantitative RT-PCR was performed using TaqMan®
RNA to-CT™ 1-Step Kit (Applied Biosystems, Foster City, CA). RNA was extracted
from the samples as described above. RNA volume equivalent to 20ng was included as
the template for the qRT-PCR reactions. Reactions included Taqman® RT-PCR Mix
(2x)(Applied Biosystems), Taqman® RT Enzyme Mix (40x)(Applied Biosystems,
Foster, City, CA), and Taqman® Gene Expression Assay (20x)(Applied Biosystems,
Foster City, CA) as recommended by the manufacturer. Gene expression assays using
ABI Taqman primers (Applied Biosystems, Foster City, CA), previously validated by the
manufacturer, were completed to quantify gene expression, see Table 1 for complete list.
All reactions were run in triplicate. Reactions that did not contain any RNA template
were included as negative controls. Reactions were processed on an Applied Biosystems
7900HT Sequence Detection System.
The run method used the following conditions:
Standard mode
Reverse transcription

48C for 15 minutes

Activation of AmpliTaq Gold® DNA polymerase, Ultra Pure

95C for 10 minutes

Cycle 40x

Denature

95C for 15 seconds

Anneal/Extend

60C for 1 minute

Amplification data was analyzed with the ABI Prism SDS 2.1 software (Applied
Biosystems). Relative quantification of gene expression was performed by the ∆∆Ct
method. GAPDH expression served as the endogenous control to normalize expression
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within each sample measurement. HDMEC, endothelial cells, were used for the
comparative relative expression.
Statistical Analysis
Hemangioma phases, proliferative, early quiescent, late quiescent and involuted,
were compared with the three endothelial controls using a one-way ANOVA, p<0.05,
followed by a post hoc Tukey HSD to identify any omnibus F value obtained. Analyses
were done using SPSS. Relative expression (∆∆Ct) is expressed via a log2 scale and thus
traditional standard deviation calculations are not sufficient. The upper and lower error
bounds are not linear. To calculate upper error this formula was used: UE=2^-((∆∆Ct) SD of ∆∆Ct)). To calculate the lower error this formula was used: LE=SD of ∆∆Ct –(2^(∆∆Ct))

Summary of Methods
Performed by Student:
•

Immunohistochemistry staining

•

Specimen Collection

•

RNA extraction

•

qRT-PCR

•

Statistical Analysis

Performed as Services:
•

Immunofluorescent (Raj Martinez-Sawh, Yale medical student)
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RESULTS
Immunohistochemistry Staining
The H&E staining shows a high density of cells within a multinodular formation
with microvessels formed throughout the nodule. Red blood cells can be seen within the
microvessels. The GLUT1 staining is positive but limited to the perivascular cells and
the red blood cells serve as an internal control as they also stain positive. Similar to
GLUT1, dlk positively stained the perivascular cells. SMA positively stains more
extensively throughout the perivascular areas. Nestin stains the perivascular cells
positively throughout the hemangioma tissue and is seen weakly throughout the nodules.
Desmin, PDGFRβ and NGFR did not stain the hemangioma tissue. See Table 2 and
Figures 6 and 7.
Figure 6: Positive immunohistochemistry staining
Each of the panels shows positive staining. In the higher magnification images (40x) it is
clear that the positive staining is seen in the perivascular cells: (a) shows GLUT1 staining
which is positive and limited to the perivascular cells, (b) shows dlk, which shows similar
staining to GLUT1, limited to the perivascular cells, (c) SMA stains the perivascular cells
but goes beyond the immediate periluminal cells and (d) Nestin also stains the
perivascular cells but also shows positive staining weakly throughout the tissue.
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Figure 6: Positive immunohistochemistry staining
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(c)

Nestin

(d)

23

Figure 7: Negative immunohistochemistry staining
In contrast to the previous Figure 6, each of these antibodies (a) desmin, (b) PDGFR-β
and (c) NGFR did not positively stain the hemangioma tissue.

20x

40x

H&E

10x

Desmin

(a)

PDGFR-β

(b)

NGFR

(c)
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Immunofluorescence Staining
Indiret immunofluoresence showed GLUT1 staining the cells lining the
microvessels as well as weakly throughout the hemangioma tissue. CD31, an endothelial
cell marker, positively stained the cells lining the microvasculature of the lesion. Sox2, a
nuclear stem cell marker, stains the nuclei of the cells throughout the hemangioma.
Nestin, a stem cell and neural crest marker, stains the perivascular cells. Figure #

SMA

and calponin, pericyte markers, stains the perivascular cells of the microvessels. NG2, a
pericyte and neural crest marker, is weakly positive throughout the tissue. See Table 2
and Figure 8 and 9. PDGFRβ, NGFR and Sox10 did not stain the hemangioma tissue,
Figure 10.

Figure 8: Positive immunofluorescence staining: stem cell and neural crest markers
Shown are the results of indirect immunofluorscence on formalin fixed paraffinembedded tissue (color-coded to match the fluorophore). DAPI staining visualizes the
nuclei; (a) shows GLUT1, the diagnostic marker for hemangiomas, staining the cells
lining the capillaries as well as weakly throughout the tissue; (b) shows CD31, an
endothelial cell marker, lining the microvasculature of the lesion; (c) shows Sox2, a stem
cell marker, staining and (d) is the corresponding merged image with DAPI; (e)
demonstrates positive Nestin staining, a neural crest marker.
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(a)

GLUT1/DAPI
(c)

Sox2

(b)

CD31/DAPI
(d)

Sox2/DAPI
Figure 8: Positive immunofluorescence

(e)

staining: stem cell and neural crest
markers

Nestin/DAPI
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(a)

SMA/DAPI

(b)

DLK/DAPI

(c)

(d)

Calponin/DAPI

NG2/DAPI

Figure 9: Positive immunofluorescence staining: pericyte markers
Shown are the results of indirect immunofluorescence on formalin fixed paraffinembedded tissue (color-coded to match the fluorophore). DAPI staining visualizes the
nuclei; (a) shows positive staining for SMA in the periluminal regions; (b) indicates that
dlk is more diffusely positive but with increased concentration in the periluminal regions;
(c) demonstrates intense calponin staining around the luminal borders; (d) shows weakly
positive and diffuse, NG2 staining.

27

(a)

(b)

NGFR/DAPI

PDGFR-β/DAPI
Figure 10: Negative

(c)

immunofluorescence staining
Each of these antibodies (a) NGFR, (b)
PDGFR-β and (c) Sox10 did not stain the
hemangioma tissue. The basement
membrane of the epidermis is a positive
control for Sox10. The negative staining

Sox10/DAPI

of NGFR and PDGFR-β is consistent with
the immunohistochemistry staining seen in
Figure 7.

Samples
RNA was extracted from 15 samples and included in the study. The mean age of
the child at the time of excision for the proliferative group (n=5), early quiescent group
(n=3), late quiescent group (n=4) and involuted group (n=3) phase was 255±113 days,
151±51 days, 1140±550 days and 2013±1471 days, respectively, Table 3
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Table 3: Descriptive statistics for hemangioma samples
Age at Time of Excision (days)
Hemangioma Phase
Proliferative
Early Quiescent
Late Quiescent
Involuted
All Phases

N
5
3
4
3
15

Mean

Std. Deviation
255
161
1141
2014
824

113
51
550
1471
959

Quantitative Real Time – Polymerase Chain Reaction
Descriptive statistics for the mean relative expression of each of the probes to
HDMEC cells are presented in Table 4. All of the gene expression analyzed had a mean
relative expression greater than the HDMEC control, Figure 11. Each of the gene
expression analyzed compared using a oneway ANOVA at α = 0.05 revealed a
significant difference among the hemangioma phases. There were three significant
differences found: Sox9 (F 3,7 = 28.760, p<0.000), C/EBPβ (F 3,7 = 4.776, p = 0.041),
and KLF2 (F 3,9 = 4.064, p = 0.044), Table 5. No other significant differences were
found. A post hoc Tukey’s HSD was used to identify the source of the significant
omnibus F for Sox9, C/EBPβ and KLF2, Table 6 and Figure 12. It indicated that the
relative expression of Sox9 was significantly greater in the involuted phase compared to
the proliferative, early quiescent and late quiescent phases. Also, the relative expression
of C/EBPβ was significantly greater in the proliferative phase compared to the early
quiescent phase. Finally, the relative expression of KLF2 was significantly less in the
proliferative phase compared to the late quiescent phase. No other differences were
found.
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Figure 11: Hemangioma relative expression of mRNA markers
qRT-PCR mean relative expression (2^(-∆∆Ct)) ± upper and lower error bounds for mRNA targets in hemangioma samples (n=15)
calibrated to endothelial control (HDMEC) expression. GAPDH expression to normalize. Graphed on a logarithmic scale.
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Figure 12: Hemangioma phases relative expression of mRNA markers
qRT-PCR mean relative expression (2^(-∆∆Ct)) ± upper and lower error bounds for mRNA targets for hemangioma phases.
# indicates graph is on a logarithmic scale. * significant difference
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Continued Figure 12: Hemangioma phases relative expression of mRNA markers
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DISCUSSION
Hemangiomas clearly express stem cell, neural crest and pericyte markers. The
immunohistochemistry and immunoflourescent data allows for visualization of markers
in the histopathology structure. GLUT1 is the diagnostic marker of hemangiomas. The
cells that stain positively for GLUT1 are the periluminal cells which make these cells of
interest in regards to investigating the origin of the hemangioma. Specific pericyte
markers, SMA, dlk and calponin, stain the same areas as GLUT1 indicating that the
hemangioma cell is likely a pericyte-like cell. Although, desmin and PDGFRβ did not
stain positive. These markers typically indicate mature pericytes and it is not surprising
that hemangioma cells do not express these markers.
Nestin, a stem cell and neural crest marker, stains similar perivascular cells as
GLUT1 indicating that the hemangioma cell type may have a neural crest and stem cell
derivative. NG2 is a pericyte and a neural crest marker and interestingly stains weakly
throughout the tissue indicating that the hemangioma tissue may be derived from a neural
crest cell. Similarily, Sox2, a stem cell marker, stains diffusely throughout the
hemangioma tissue. The specific staining of the hemangioma perivascular cells with
stem cell, neural crest and pericyte markers supports the theory posited in this work.
Diffuse stem cell markers throughout the tissue support that hemangioma cells are
capable of pluripotent differentiation.
The qRT-PCR data also supports expression of stem cell (Sox2, Pauf5, Nanog,
Sox9), neural crest (NGFR) and pericyte (dlk) markers in hemangiomas. Each of these
mRNAs were expressed at least a 10-fold expression greater than the control endothelial
cells. Previous data collected by this lab via FACS analysis showed that hemangioma

cells were more like pericytes than endothelial cells as they expressed CD90(Thy1) and
NG2, Figure 14.
Figure 14: Fluorescence Activated Cell Sorting (FACS) analysis
As shown here, previous work done by this laboratory revealed through a FACS analysis
that the hemangioma cells express two pericyte-specific markers that endothelial cells do
not possess.
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Each of the adipocyte differentiation factors investigated had a relative expression
greater than the endothelial cells. The RXR and SREB receptors had the lowest relative
expression compared to the endothelial cells and was more consistently expressed at that
low level throughout the hemangioma phases. Dlk and Sox9 demonstrated the most
increase in fold expression compared to endothelial cells. Not surprising that their levels
mirrored each other as dlk is an influencing factor on Sox9 expression. Dlk is the major
inhibitory molecule for adipogenesis and Sox9 directly binds to the promoters of C/EBPβ
and C/EBPδ, early pro-angiogenic factors. Late differentiation factors, C/EBPα and
PPARγ, also displayed a relative expression greater than endothelial cells. The KLFs
investigated all had relative expression greater than endothelial cells. KLF2, an
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inhibitory factor, had the greatest relative expression while KLF15, a proadipogenic
factor, had the least relative expression.
Unfortunately, only three significant differences were found between the
hemangioma phases. Sox9 was found to be greater in the involuted phase when
compared to each of the other phases. This may indicate that adipogenesis is an ongoing
process during hemangioma growth and proliferation and in fact the angiogenic growth is
accompanied by adipogenesis. The involuted phases may actually represent either fully
differentiated epidermal and soft tissue cells or potentially the hemangioma cells have
undergone apoptosis, subsequently leaving normal tissue behind. Scarring that is often
observed after a hemangioma has involuted may be a consequence of increased
inflammatory molecules in the area of the hemangioma.
C/EBPβ was expressed greater in the proliferative phase compared to the early
quiescent phase. This factor is expressed early in adipocyte differentiation. Again,
proliferating hemangiomas may actually represent a balance between angiogenic and
adipogenic differentiation. It is possible that as lesions begin to slow in growth during
the quiescent phase and adipocyte differentiation begins to phase into the terminal
differentiation phases.
Finally, KLF2, an inhibitor of adipogenesis, was significantly greater during the
late quiescent phase compared to the proliferative phase. This follows the theory that
pluripotent differentiation occurs during the early proliferative phases and as the lesion
matures, the cells either fully differentiate into their end product or possibly they undergo
apoptosis. KLF2 being less expressed in the proliferative phases would allow for early
adipocyte differentiation. KLF2 being higher expressed in the late quiescent phase
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indicates that the cells are less likely to undergo adipocyte differentiation or that the
KLF2 is able to slow or even regress the adipocyte differentiation. KLF2 inhibits
adipocyte differentiation via inhibition of PPARγ expression. PPARγ is the positive
regulator for adipocyte differentiation and is required for mature adipocytes to be
maintained. If KLF2 is increased older lesions, it is possible to question if KLF2 can stop
adipocyte maturation, can cause regression of adipocytes to a less mature state or even
apoptosis of the affected cells. Many questions remain about the influences of the
adipocyte differentiation transcription cascade on hemangioma development and
progression.
The limitations of this study must be acknowledged. Gene expression profiling
gathered through qRT-PCR in animal and human specimens are subject to scrutiny based
on the extreme variability of gene expression and transient nature of many proteins in
vivo. Hemangiomas are no exception. The lesions are a small microenvironment in the
host patient and any analysis of hemangioma tissue represents ongoing and concurrent
processes within the lesion as well as variability among patient. Moreover, the
heterogeneity of hemangiomas has always been clinically apparent. The qRT-PCR data
further capitulates the variability among these lesions as demonstrated by the wide upper
and lower errors for the relative expressions.
The sample size and the phase criteria can also be criticized. The statistical power
of the study is limited by the small sample size (n=15) and the complex comparisons
needed. In the literature, many authors use the age of the child as the defining factors
between proliferative and involuting lesions. In order to best determine “like” lesions we
relied heavily on two individual surgeon’s notes in order to delineate proliferative,
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quiescent and involuting lesions. We believe that clinical appearance is more important
to the underlying pathology and microenvironment compared to the quantitative age of
the child at time of excision. Counter intuitively, the early quiescent lesions were
younger on average than the proliferative lesions; however, there was no significant
differences between the mean ages between the two groups (t-test, p=0.23). Age
continues to be important; however, clinical observation appears to be more consistent
with mRNA expression profiles.
Furthermore, the data presented is based on the ∆∆Ct method of calculation for
relative expression compared to endothelial cells. Endothelial cells were chosen as the
comparative sample because aberrant endothelial cells remain a well-accepted source for
the cell of origin for hemangiomas. To strengthen this study, relative expression
compared to adipocytes would increase the ability to identify the similarities, if any exist,
between hemangioma cells and adipocytes. Additionally, using a standard curve would
provide a stronger quantitative analysis for comparison between control samples and
among hemangioma phases.
Although definitive conclusions are difficult to draw based on the discussed
limitations of qRT-PCR, including the small sample size of the study and variability
among the patients, it is clear that the qualitative relative expression compared to
endothelial cells exists for the markers examined. The comparison between the
hemangioma phases is a pioneering attempt to better qualify the characteristics of
quiescent lesions. Once a lesion has stopped growing, answering the parents’ question:
“how long will this lesion be on my child?” is difficult to do.
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Hemangioma pathophysiology is likely more complicated than originally
anticipated with multiple processes (including adipogenesis, angiogensis and possibly
apoptosis) occurring in a concert of balanced control shifts. Research on the quiescent
and involutive phases of hemangiomas may identify molecular markers that can be used
for treatment targets or prognostic screening.
A number of observations, although not statistically significant, are worthy of
discussion. It appears that the overall quantity stem cell and neural crest markers
decrease over time. It might be inferred that as the lesions mature their pluripotent ability
decreases along with the stem cell markers. Also, one would expect a fibrofatty tissue to
exhibit PPARγ, a marker of mature adipocytes. In fact, the PPARγ expression was the
lowest, though not significant in the involuted lesions. Remembering that involuted
lesions are either normal tissue or a fibrofatty scar, the low level of PPARγ goes along
with the idea that tissue can revert to normal tissue. The fibrofatty scar may in fact be the
result of inflammation from the proliferative process that leaves scar tissue in the place of
the hemangioma.
In regard to the KLFs, it is difficult to extrapolate a pattern. One can state that
KLFs are indeed expressed in hemangiomas but at this time it is too intricate to infer the
exact mechanism of control they have on hemangioma proliferation and involution.
Likely the control that KLFs have on hemangioma progression is complex and involves
not only adipocyte differentiation but angiogenesis and pluripotency capabilities, as well.
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FUTURE STUDIES
Future studies are needed to investigate a number of areas left unexplained. This
thesis represents a work in progress and additional experiments await completion. A list
of partially complete and anticipated experiments is below.
•

Confirm expression of mRNAs examined by qPCR with western blot

•

Culture hemangioma cells and pericyte cultures (complete)
o Treat with thiazolidinediones (TZD)


PPARγ agonist, promotes adipocyte differentiation



Preliminary work with Red-O staining indicates fat production
within hemanigioma and pericyte cells



Possibly a novel treatment option for quiescent lesions

o Silence dlk with a shRNA lentivirus vector


Dlk is the main inhibitor of adipocyte differentiation



Show that dlk is an inhibitor of hemangioma involution



Preliminary data indicates explants are capable of transfection,
allowing for hemangioma macrostructure to remain intact

•

Animal study
o Explant proliferating hemangioma into nude mouse
o Treat with TZD

•

Identify single nucleotide polymorphisms at the dlk gene locus
o

Possible screening tool
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CONCLUSION
The work presented in this thesis is novel and informative. It demonstrated that
hemangiomas indeed express a number of stem cell, neural crest and pericyte markers.
This is the first study to identify factors involved in adipocyte differentiation including
dlk, PPARγ and KLFs. The data presented provides support for the hypothesis that
hemangiomas are pericyte-like stem cell tumors derived from the neural crest capable of
adipocyte differentiation. Further work will be needed to definitively identify the cell of
origin and optimal treatment for hemangiomas.
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SUPPLEMENT TEXT
Clinical Features of Hemangiomas
Hemangiomas are the most common benign tumor in the pediatric population
with an overall incidence estimate of 4 to 5%1 although earlier studies estimated 9 to
13%.16, 20, 24, 25 Prior studies observed a marked female preponderance compared to males
at a ratio of 3:1,15, 16, 24-28 a predilection for light skin types,27, 67 and a higher incidence
among premature infants, especially those weighing less than 1,500g.8, 28, 29 Lesions are
seen predominantly in the head and neck region with a nonrandom distribution.6-9
Hemangiomas are a well-studied tumor from a clinical standpoint. The lesion
typically appears within weeks of the infant’s birth but is not present at the time of birth.
Grossly, an erythematous patch or a telangiectasia may be seen within hours to days of
birth which then develops into an elevated red to purple lesion.3 The lesion is primarily
composed of microvascular components in which angiogenesis is initially excessive,
termed the proliferative phase, for approximately 1 year after birth. Microscopically, the
proliferative phase is identified by endothelial proliferation and hyperplasia with and
without lumin formation in a multilobular pattern.2-4 Other cell types involved include
mast cells, macrophages, plasma cells and pericytes.68 This is followed by the involuting
phase consisting of a slow but inevitable regression of the disorganized vessels. Mature
blood vessels form with multi-laminated basement membranes. These mature blood
vessels are found among predominately adipocytes and connective tissue, termed a
fibrofatty residuum.7, 20, 21, 69 See Figure 1 for typical presentation.
Traditionally described, involution occurs at approximately 10% per year, with
50% of lesions involuting by 5 years of age, 70% by 7, and 90% by 9.70 Complete
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involution of the lesion often occurs, leaving no clinical evidence of the hemangioma;
however, nearly half of affected children will retain fibrofatty tissue or have scar
formation at the site of the lesion.22, 23
Diagnosis is made with a high degree of confidence on the basis of strong
immunoreactivity with antibodies against the glucose transporter protein isoform 1
(GLUT1).10-13 This assists in the differentiation between normal vasculature of the skin,
vascular malformations, and other benign vascular tumors (pygonic granuloma, tufted
angioma and kaposiform hemangiomendothelioma) which are not GLUT1 positive.13
Most (~80%) hemangiomas are solitary in their presentation and create little
concern due to their benign course.8, 71 For these lesions, “watchful waiting” is an
appropriate conservative approach to treatment when size, location, and behavior are
unlikely to result in functional impairment or deformity. Unfortunately, 10 to 20% of
infants will suffer a complication secondary to the lesion and require treatment.68 The
most common complication is ulceration which occurs in approximately 5% of affected
children.15 Ulceration is associated with pain and blood loss and, in severe cases,
necrosis can lead to loss of soft tissue including nose, ear and lip structures.15, 16 Infants
can suffer from poor feeding and sleeping resulting in failure to thrive and even death
from infection.15, 16
Additional complications occur secondary to size and location. For example, a
hemangioma in the periorbital region blocking a child’s visual field or compressing the
globe can lead to visual development impairment, astigmatism, amblyopia, exposure
keratopathy, proptosis, and ptosis.16, 17, 72-74Another situation, involves lesions near the
ear which can obstruct the external auditory canal and result in chronic/intermittent otitis
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or decrease auditory conduction which can eventually lead to delayed speech
development. 16, 75-77
The location of lesions can indicate further underlying pathology. Over half of
children with lesions in the “beard” distribution (preauricular areas, the chin, anterior
portion of the neck, and lower lip), shown in Figure 4 , have associated lesions in the
orapharyngeal or subglottic region which can cause symptomatic airway obstruction
requiring tracheostomy.16, 18 Furthermore, lumbrosacral lesions can be associated with
underlying tethered spinal cord, urogenital and anorectal anomalies and these infants
should be evaluated for such anomalies.78
Also, the number of lesions can signify further underlying pathology. Multifocal
presentation or “disseminated hemangiomatosis” defines an infant with greater than 5
cutaneous hemangiomas, typically 1 to 10mm in diameter.71, 79 Infants are at a higher
risk of visceral hemangiomas and should be evaluated for lesions involving the liver,
brain, gastrointestinal and lung. 80-82 These patients are also at risk for high-output
cardiac failure,83, 84 gastrointestinal bleeding, hydrocephalus and consumption
coagulopathy (aka Kasabach-Merrit syndrome).81, 82, 85
Of diagnostic and clinical importance is a subgroup of patients with large (>5cm),
often termed “segmental,” hemangiomas, an example is shown in Figure 4. These
hemangiomas are associated with structural anomalies of the brain, cerebral vasculature,
eyes, aorta, and chest wall. This is known as the neurocutaneous disorder called PHACE
syndrome (OMIM 606519).86 The PHACE acronym refers to posterior fossa anomalies,
hemangioma, arterial lesions, cardiac abnormalities/aortic coarctation, and abnormalities
of the eye.60
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Treatment Modalities and Mechanisms for Hemangiomas
Many treatments target associated symptoms such as antibiotics for infection,
anti-inflammatories, narcotics for pain and barrier agents for friction prevention. These
modalities do little in regards to hastening the involution of hemangiomas. The known
pharmacologic agents that quicken hemangioma involution are corticosteroids,
chemotherapy agents (examples: interferon α, vincristine and cyclophosphamide) and
propranolol. Physicians often utilize these drugs as well as laser and surgery to improve
the symptoms and outcomes for the affected children. However, each of these treatments
is associated with an adverse side effect profile as discussed below.
Cryotherapy
Although not used widely in the United States, cryotherapy use is indicated
particularly for superficial and peduculated hemangiomas and is used more often in
Europe and South America.16, 87-89 Use of this therapy is criticized because the risk of
hypopigmentation and atrophic scar formation exists.16, 87, 89
Corticoidsteroids
Zarem and Edgerton reported, in 1967, a case series of patients with
hemangiomas that responded to prednisolone90 and from that point in time corticosteroids
became the mainstay treatment for problematic hemangiomas. Oral corticosteroid
therapy continues to be effective in stopping the growth of hemangiomas but the response
is variable.91, 92 Potential adverse effects include cushingoid features, growth retardation,
gastroesophageal reflux, ulceration, hypertension, hyperglycemia, glycosuria, behavioral
disturbances, and immunosuppression; yet upon cessation of the drug these side effects
all regress.93-96 The recommended dosage is 2-5 mg/kg/day methprednisolone or
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prednisone for 3 to 4 weeks with a gradual taper.15, 16 If no response is noted within 8 to
10 days, the treatment should be stopped and alternative therapies should be employed.89
The effectiveness of corticosteroids is noted only in actively proliferating lesions and
involuting lesions should be treated with other therapies.23
Intralesional steroid injections, typically 3-5 mg/kg triamcinolone,15, 16, 92 are used
for the treatment of problematic subglottic and periorbital lesions and their use is noted
particularly in the otolaryngology literature.97-100 Concern in regards to periorbital lesion
injections exists because central retinal artery occlusion, ophthalmic artery occlusion and
retinal embolization can occur.101-104 Proponents for this treatment believe that with the
correct dose and delivery complications can be avoided.105, 106
Although the exact mechanism remains unknown for how steroids inhibit
proliferating hemangiomas, it likely involves inhibition of angiogenesis. Steroids exert
their effect by binding directly with steroid receptors. The steroid-receptor complex is
then capable of binding to the gene DNA at a glucocorticoid response element (GRE)
which modulates promoter activity. This interaction leads to direct altered gene
expression of between 10 and 100 genes which is cell-type and environment dependent.
The effects of steroids on hemangiomas are likely related to pro-angiogenic
factors. Hasan et al. found that in a hemangioma injected with intralesional steroids that
these factors were decreased: platelet-derived growth factor-A and –B (pro-angiogenic);
interleukin-6 (pro-inflamatory, smooth muscle); transforming growth factor-b1 and -b3
(pro-apoptotic), while these factors remained unchanged: basic fibroblast growth factor
(pro-angiogenic) and vascular endothelial cell growth factor (pro-angiogenic).107 Likely
it is the decrease in these factors that influences the angiogenesis.
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Furthermore, the same group found an up-regulation of mitochondrial cytochrome
b (cyt b) in hemangioma tissue following steroid-induced and natural involution.107, 108
Cyt b is a component of the mitochondrial respiratory chain and the location of this gene
in the mitochondrial DNA is close to sequences that resemble GREs, the promoter
sequences that bind steroid-receptor complexes.109 Elevated expression of cyt b was also
observed in senescent human cells110 and involuting lactating gland following
weaning.111 The postulation is that the increased oxygen metabolism inhibits
proliferation.
Chemotherapy Agents
Chemotherapy agents are another tool in the physician’s armamentaria saved for
problematic corticosteroid-resistant hemangiomas. This review will focus on the past and
present treatments used more universally although it should be noted that there are other
treatment modalities in the literature. Other modalities not discussed include intralesional
bleomycin112 and topical imiquimod(Aldara; Graceway Pharmaceuticals, LLC, Bristol,
TN).113-116
Interferon-α
Interferon-α (IFN-α) originally developed as an antiviral agent was subsequently
discovered to have a range of activities including immunemodulting, anti-proliferative,
and antiviral.117, 118 Anti-angiogenic and anti-tumor properties was unexpectedly found
when treating patients with human immunodeficiency virus (HIV) infection with IFN-α
and subsequently their Kaposi’s sarcoma, a vascular tumor associated with
immunodeficiency, improved.118-122
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IFN-α’s anti-angiogenic properties were first reported in 1980 by Brouty-Boye
and Zetter that showed that IFN inhibited capillary endothelial cell migration in vitro.123
Studies further supported the inhibitory action on endothelial migration and proliferation
in vitro124 and in vivo.125 IFN-α may act indirectly by inhibiting pro-angiogenic stiumuli
such as growth factors involved in collagen production and the proliferation of
endothelial cells, smooth muscle cells, and fibroblasts.126
IFN-α therapy was implemented in 1989 by White et al. and Orchard et al. to
several severe cases by of hemangiomas with positive responses.127-129 After these initial
cases, IFN-α become the second-line agent for corticosteroid-resistant hemangiomas.130
Unfortunately, a case series reported spastic diplegia, a condition of hypertonia
and spasticity in the muscles of the lower extremities, developing in 20% (5 out of 26) of
children treated with IFN-α for hemangiomas. Paralysis was permanent in 3 of 5
children.131, 132 Due to the severe adverse effect, IFN-α dropped out of favor as the
treatment of choice for corticosteroid-resistant hemangiomas.
Vincristine
Vincristine is a mitotic inhibitor that acts on tubulin dimmers and inhibits the
assembly of microtubules structures. The use of vincristine for the treatment of
hemangiomas was prompted by Ghadially’s finding that identified high tubulin content in
endothelial cells,133 a major blood vessel component. Inhibition of tubulin in
hemangioma-associated endothelial cells ceases the proliferation of the lesion. The
current dose is given intravenously on a weekly basis. The dosage is 0.05mg/kg in
children less than 10 kg or 1.5mg/m2 in infants greater than 10kg.95 Adverse side effects
are dose-related and reversible and include gastrointestinal upset, constipation, fever,
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headache, and peripheral and autonomic neuropathies.134 Vincristine has replaced IFN-α
as the second-line agent in problematic corticosteroid-resistant lesions because of the
more benign side effect profile.134-137 This agent has been used for treating lifethreatening kaposiform hemangioendothelioma associated with Kasabach-Merritt
syndrome.138-140
Cyclophosphamide
Cyclophosphamide is an alkylating agent introduced by Rush in 1966 to treat a
giant cutaneous hemangioma that was resistant to the sclerosing agent sodium
morhuate.141 Since this initial report, a handful of authors have published cases
successfully using cyclophosphamide in patients with life-threatening hemangiomas.142147

The proposed mechanism of cyclophosphamide in hemangiomas is that it blocks
the proliferation of new capillaries resulting in shrinkage, fibrosis and subsequent
regression of the tumor. The published treatment dose is 10 mg/kg per dose for 3 or 4
days intravenously or orally for 2 or 3 courses.142, 144, 146, 148 Consequent severe side
effects include hematologic toxicity, hemorrhagic cystitis, avascular necrosis,
cardiomyopathy, pulmonary fibrosis, gonadal damage and subsequent maliganacies.95, 149
Proponents state the low-dose and limited administration decrease the risk of such
adverse effects.95, 149
Propranolol
Propronolol is a non-selective β blocker and the most recent addition to the
physician’s arsenal for treatment of hemangiomas. It was discovered in 2008 as two
children showed rapid regression of lesions while they were being treated for
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cardiopulmonary conditions.150 A subsequent case series demonstrated excellent
regression with no noted severe associated side effects.151 Other authors have also noted
similar efficacy.152-156 The current recommended dose is 2 mg/kg/day. Potential side
effects of β-blockers include bradycardia, hypotension, hypoglycemia, rash,
gastrointestinal discomfort/reflux, fatigue and bronchospasm. Although the least
dangerous of all the medical treatments at this time, patients are admitted for observation
to receive their first doses to ensure they are stable on the medication.
The mechanism of action for propranolol remains unknown. One prospective
explanation is vasoconstriction which decreases the blood flow to the lesion. Propranolol
was also found to reduce the pro-angiogenic factors: VEGF and bFGF and lead to
increased apoptosis of capillary endothelial cells through the down regulation of the
RAF-mitogen activated protein kinase pathway.150, 157 Another group found that this
agent inhibits tubulogenesis and matrix metalloproteinase-9 (MMP-9).158 These
observations create an argument for an anti-angiogenic property of propranolol.
Laser
The first reports of using a laser for treatment of vascular lesions were with argon
lasers by Apfelberg et al. and Hobby, 1976 (488nm) and 1983 (514nm), respectively.159,
160

The argon laser worked well for superficial port wine stains because of shallow

penetration; however deeper, more involved lesions such as hemangiomas did not
respond as well.161 Substantial risk of complications exist secondary to nonspecific
damage to healthy epidermis and dermal tissue resulting in hypertrophic scaring, atrophic
scaring, hypopigmentation, hyperpigmentation, purpura, edema, blistering, and
ulceration.161-164

49

Laser therapy improved in the 1980’s based on the theory of selective
photothermolyisis which stated that certain macrostructures could be selectively targeted
for thermal destruction through specific radiant energy absorption. Flash lamp-pumped
pulse dye laser (575nm to 600nm) with surface cooling technology drastically improved
outcomes by decreasing nontarget thermal damage by spacing out the exposure. 165-168
The general premise of how lasers treat vascular lesions is (1) the laser radiant
energy is emitted at a particular wavelength, (2) the energy is absorbed by a certain
chromophore, in this case the target is oxyhemoglobin (585nm), and (3) subsequently that
radiant energy is converted to thermal energy within the target. By laser targeting
hemoglobin, thermal damage occurs within the targeted blood vessels. Ideally, minimal
absorption occurs superficially in the epidermis and dermal layers. However, melanin
within the epidermis also absorbs the radiant energy which can result in damage and
scarring and also limits the energy delivered to the underlying vessel pathology.
Another laser currently used is called a neodymium-doped yttrium aluminum
garnet laser (Nd:YAG) (1064nm) and it can be used alone. It can also be converted to a
frequency-doubled Nd:YAG where a Nd:YAG laser is passed through a potassium-titanyl
phosphate crystal which halves the wavelength (doubling the frequency).169 For
example, the wavelength is cut in half from the original 1064nm to 532nm. This
frequency-doubled Nd:YAG laser setup allows for longer and variable pulse duration
with less complications and is effective for deeper penetration of lesions 170, 171 and
intralesional photocoagulation.172-174 Dynamic epidermal cooling is now standard with
most laser treatments to decrease the nonspecific thermal damage to superficial and
surrounding healthy tissue. 175-178
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Surgery
Surgery is typically reserved for those children with life or sensory-threatening
lesions, though the threshold for the individual surgeon and family varies. There is no
consensus on which lesions require excision and which qualify for the “wait and watch”
philosophy. Much has been made of early psychological milestones. One undeniable
advantage of surgery is its rapid and definitive effect.179 Excision surgery can pose a risk
of hemorrhage; however, with proper technique and operative planning, this can be
avoided. The other major complication among patients undergoing excision surgery is
related to anesthesia, which can be significantly riskier in younger children. If surgery is
indicated or opted, it is critical to ensure a pediatric care team.
Hypothesis for Pathogenesis
Hemangiomas are clinically well-studied pediatric tumors; however, very little is
known about their origin. Hemangiomas share the defining characteristic of endothelial
proliferation which eventually turns into a fibrofatty residuum. There is no clearly
identifiable causal event associated with appearance of a hemangioma. Observations
have lead to proposed theories. The following will detail a number of theories posited
including: viral, a placental embolic event, genetic mutations, endothelial progenitor
cells, developmental field defects, the role of hypoxia, and angiogenesis factors.
Viral
A previous theory associated the link of Kaposi sarcoma, an endothelial cell
tumor, to human herpes virus-8; however, this link was not found in hemangiomas.180
However, another viral association discovered was that recombinant avian leukosis
viruses of subgroup J were isolated from field infected commercial layer chickens with
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multiple surface and visceral hemangiomas.181 These hemangiomas were histologically
similar to those present in humans.
Aims at designing an endothelial tumor animal model found that the injection of
mouse endothelioma cells known to have polyoma virus, a DNA tumor virus, which
express middle T oncogene (PyMT, an early region gene), is capable of inducing
hemangioma formation in adult and neonate species.182 Hemangioma rapid growth under
these conditions was associated with cell recruitment rather than local proliferation.182, 183
Almost 20 years later, direct transfection of a replication-competent avian splice
retroviral vector with PyMT using the stem cell leukemia (scl/tal-1) gene promoter and
tva retroviral receptor resulted in lethal hemangioma development in vivo, similar to the
prior study.184 Both these animal models provide an endothelial tumor model similar to
the often lethal Kasabach-Merritt syndrome in humans. These models and the associated
avaian leukosis virus in chickens provide possible insight into more involved forms of
hemangiomas but fail to provide substantial support in regards to the more common
solitary benign lesions in human infants.
Placental Embolic Material
Considerable support for a placental origin for the hemangioma exists.
Observations found that the incidence of hemangiomas was higher among children of
women who underwent chorionic villus sampling compared to children of women who
did not undergo the procedure.185-187 The theorized mechanism is that placental injury
and intravascular shedding of placental chorionic villi cells are capable of embolizing to
receptive fetal tissues, especially to areas with high blood flow such as the head and neck.
188

After delivery, removal of the embolized cells from maternally secreted anti-
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angiogenic factors, like VEGF sequestering transmembrane receptor, sFlt-1, and the
period of birthing hypoxia results in release of angiogenic factors such as VEGF. These
events create a proangiogenic environment for the embolized placental cells.16, 189-192
Proponents of this theory note that the unique self-limited growth of the hemangioma
mirrors the life-cycle of placental endothelium.188, 193
Furthermore, studies demonstrated a striking resemblance of hemangioma vessels
and placental vessels including glucose transporter 1 (GLUT-1), merosin (α-2 laminin),
Lewis Y, FcγRII (CD32), type III iodothyronine, indoleamine 2, 3 deoxygenase, and
insulin-like growth factor 2 (IGF-2).11, 12, 46, 194-196 GLUT-1 is not expressed in normal
skin microvasculature but it does stain positively in blood-barrier tissues including the
placenta, erythrocytes, nerve endoneurium and perineurium.11 Merosin is only expressed
in the placental chorionic villi, trophoblast, nervous system, eye, skeletal muscle and
dermal-epidermal junctions.197-200 Lewis Y and FcyRII are found only in placental
chorionic villi, perivascular macrophages and microglia.201 Also, a preferential gene
expression profile between hemangioma tissue and placental tissue identified similar
genes including 17-β hydroxysteroid dehydrogenase type 2 and tissue factor pathway
inhibitor 2.193, 202 Interestingly, factors found to support placental growth have also been
linked to hemangioma lesions and include epidermal growth factor (EGF), IGF1, IGF2
and FGF4.46, 203-215
Hemangiomas are likely not maternal placental derivatives. Genetic
investigations found that hemangiomas found no maternal microchimerism and identified
only XY cells in lesions of male infants; therefore, indicating that the lesions are
exclusively derived from the infant and therefore cannot be from the maternal placenta.51,
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216, 217

However, the possibility that the origin is a cell related to the fetal trophoblast

remains.
The trophoblast, the functional unit of the placenta, is essentially a highly
proliferative stem cell at the maternal-fetal junction. The two main differentiated
trophoblast roles are as 1) intermediate trophoblasts which establish the maternal-fetal
circulation by eroding into the maternal spiral arteries and 2) syncytiotrophoblasts
programmed to maintain and fuse with the syncytium, the maternal-fetal barrier.218 An
embolized trophoblast, possibly “let loose” during a chorionic villous sampling
procedure, could very well be either a trophoblast stem cell or a differentiated
trophoblast.
Tissue markers as noted above link hemangiomas to differentiated placental
microvasculature not necessarily trophoblast stem cells.11 To date, no study has
investigated specific trophoblast markers that may help determine the cell of origin for
the hemangioma. Syncytiotrophoblsts specific markers include Sox17 and GATA4219
while intermediate trophoblasts are identified by double staining with cytokeritin 7 and
HLA-G.220
Syncytiotrophoblasts behave less like that of a hemangioma lesion. The nature of
the intermediate trophoblast to orchestrate the microvascular formation of the maternalfetal circulation is more similar to the vascular proliferation of hemangiomas. If the
embolized cell is a differentiated trophoblast, it is likely an intermediate trophoblast and
not a syncytiotrophoblast. Human intermediate trophoblasts adopt a vascular phenotype
as they differentiate.221
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However, the behavior of the trophoblast is not only tightly regulated by a
plethery of molecular pathways222 but critical vectorial relations exist. Trophoblast stem
cells in vitro quickly exit the mitotic cycle, differentiate and fuse to form a giant cell that
degenerates in about 5 days.223 224-226 In order to overcome vectorial dependencies of
trophoblast differentiation, explant methods were developed to preserve the relationship
between the mesenchyme, basement membrane and the trophoblast epithelium. 227
Explant models allow investigation of environment and molecular pathways involved in
regulation of placental growth and development. Interestingly, explanted hemangioma
tissue into nude mice recapitulates a similar life-cycle behavior of the lesion in vivo.45
This raises the question of how an embolized trophoblast, stem cell or differentiated, is
able to structurally orchestrate and grow into a hemangioma, a complex microvascular
lesion. Further investigation is required before this theory can be accepted.
Endothelial Progenitor Cells
Endothelial progenitor stem cells which are capable of inducing postnatal
formation of vascular tissue may be critical to hemangioma pathogenesis.47, 228
Endothelial progenitor cells are stem cells capable of contributing to blood vessel
formation.229 They are identified as expressing both CD34, an endothelial marker, and
CD133, a stem cell marker. These cells have been isolated from the bone marrow, blood
circulation, fetal liver, and skeletal muscle.230, 231 They contribute to tissue
vascularization during both embryonic and postnatal physiologic processes including
vascular development, organ regeneration and tumor neoangiogenesis.232, 233 Endothelial
progenitor cells express HIF-1α which promotes local production of VEGF, angiogenesis
and mobilization of endothelial progenitor cells.234
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Endothelial progenitor cells co-expressing CD34 and CD133 were identified in
proliferating hemangiomas.235 These cells displayed unique cellular responses to
angiogenic inhibitor endostatin. The hemangioma endothelial cells had an angiogenic
mRNA expression profiles more similar to umbilical cord blood-derived endothelial
progenitor cells than to mature endothelial cells and.50, 52, 49 It is postulated that the
proliferative activity is specific to immature endothelial cells and not specifically to
hemangioma endothelial cells.236
Children with hemangiomas demonstrated a 15-fold increase in peripheral
circulation of endothelial progenitor cells at the time of resection compared to age
matched control children.237 The peripheral endothelial progenitor cells were cultured
and stained positively for previously defined markers of hemangiomas: GLUT1, CD22
and merosin.237
Developmental Field Defects
Developmental fields are parts of the embryo in which the development of
complex structures are controlled and coordinated in a spatially ordered, temporally
synchronizied and epimorphically hierarchial manner.238, 239 Disturbances in a field
development may be corrected or they may lead to anomalies or incomplete
differentiation. These disturbances can occur at any point in the developmental process
and result in different constellations of phenotype. Early action can lead to extensive
defects (e.g., cyclopic holoprosencephaly) while later actions result in a lesser defects
(e.g., cleft palate or postaxial polydactyly). Disturbances early may present with a
malformation syndrome involving two or more fields (e.g. acrorenal, cardiomelic,
gastromelic, or splenomelic anomalies).238, 239 If genetically caused, all structures

56

immediately involved consequently are genetically abnormal while those structures
affected secondarily have normal genotypes. 238
In regard to hemangiomas, specific interest in regard to developmental field
defects lies in PHACE syndrome. Posterior fossa malformations, arterial anomalies,
cardiac and eye abnormalities are consistent with an early developmental field defect that
occur at approximately 8 to 10 weeks of gestational age.240-242 The observation that
hemangiomas also occur in these patients, especially large segmental hemangiomas,
indicates that the underlying cause of hemangioma may be directed toward an early
differentiation pathway.
Genetic Disruptions
Researchers found that hemangiomas are genetically derived from the child. In
conjunction with those studies, it was found that hemangioma cells displayed allelic loss.
This loss of heterzygosity, seen in some cancers, may result in the loss of a tumor
suppressor genes allowing for growth.243 Furthermore, analysis of in vitro and by direct
tissue studies demonstrated clonality which means that hemangiomas may in fact arise
from a single aberrant cell.50, 243
Specific mutations have been identified; however, they are not consistently found
in all hemangiomas studied. Missense mutations in the genes encoding VEGFR2 (KDR),
VEGFR3(FLT4) and TEM8 (ANTXR1) were identified.243, 244 These proteins are part of
the complex which regulates the expression of VEGFR1.244 These germline missense
mutations do not appear to cause systemic vascular abnormalities. Germline mutations
seen in identified genes are probably associated with a secondary somatic event, such as
hypoxia, which triggers the expansion of endothelial cells within the lesion. These
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findings do allow inferences to the importance of the affected genes and resulting
proteins in the mechanism of pathology.
Hypoxia
The association of hemangiomas with premature infants and low birth weight
infants has been demonstrated.28, 29, 245 Premature birth is also correlated with placental
hypoxia and retinopathy of prematurity.246 Recently, studies have shown an association
between hemangiomas and placental hypoxia247, 248 as well as retinopathy of
prematurity.249
These observations bring to light the possibility that hypoxia plays a role in the
development of hemangioma. Tissue hypoxia seems to be the most powerful inducer of
angiogenesis. Hypoxia-inducible factor-1α (HIF-1α ) is the main adaptive response to
tissue hypoxia resulting in enhanced glucose uptake, increased red blood cells and the
formation of new blood vessels.250 Not surprisingly, proper placental growth is tightly
dependent on metabolism components such as oxygen, glucose, and pyruvate specifically
through HIF-1α.250
Hypoxia leads to the stabilization of HIF-1α and consequently to local production
of downstream molecules: GLUT1, stromal cell-derived factors-1a (SDF-1a), VEGF and
MMP.250-254 These factors are capable of initiating proliferation of endothelial cells.255-257
It is thought that overexpression of GLUT1 receptor allows cells to scavenge glucose
which provides energy for new vascularization as well as resist against apoptosis.254, 258
HIF-1α was found at greater concentrations in proliferating hemangiomas when
compared to involuting hemangiomas.253, 259 Herbert et al. found that hemangioma
monocyte-derived endothelial-like cells in tissue culture displayed an increase of GLUT1
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transcription and surface expression of GLUT1 protein after hypoxia treatment. 260 HIF1α and subsequent GLUT1 expression indicates that hypoxia may induce downstream
molecules favorable for the proliferation of hemangiomas. The cell culture study also
indicates that this response is likely innate to the hemangioma cell.
Serum concentrations of MMP-9 and VEGF were higher in proliferating
hemangioma patients compared to involuted hemangioma patients, vascular
malformations and control infants.261-263 Furthermore, the microenvironmental amount of
VEGF, not the total concentration of VEGF, determined normal or aberrant
angiogenesis.264 This indicates that only one abnormal cell is needed for the necessary
VEGF production to initiate hemangioma formation. 264
Angiogenesis and Vasculogenesis
Given the clinical characteristics of hemangioma, researchers anticipate the
involvement of these two processes in the pathogenesis. Angiogenesis is defined as the
growth of new blood vessels from existing vasculature, while vasculogenesis involves de
novo development of vessels from prescursor cells in situ. Angiogenesis is orchestrated
by a number of factors and environment cues. Angiogenic factors include basic
fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).214, 265, 266
One of the key environment cues for neovascularization is hypoxia which triggers the
HIF-1α production.251 Vasculogenesis is considered to be an embryonic development
process; however, recent evidence provides support for on going vasculogenic potential
in the adult with the identification of endothelial progenitor cells.
Angiogenic factors and receptors have been investigated in regards to
pathogenesis, prognosis and treatment. Vasculogenesis of the lesion is not far fetched as a
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number of potential precursor cell reservoirs exist including, dormant angioblasts,267
placental trophoblasts, and bone marrow.268 Hemangioma tissue expresses a number of
angiogenic markers and receptors including: bFGF, VEGF, MMP-9, estrogen receptors,
SDF-1a and P1GF.214, 253, 265, 269-271
Basic Fibroblast Growth Factor (bFGF)
Basic fibroblast growth factor is a 146-amino acid polypeptide member of the
heparin-binding growth factor family.266 In tissue culture, bFGF induces migration and
proliferation of endothelial cells.272 bFGF was increased in urinary excretion in patients
with vascular tumors;273 however, bFGF serum concentrations were similar among
vascular tumor, vascular malformation and healthy control patients.211 bFGF mRNA was
found predominantly in the tumor pericytes and endothelial cells indicating that bFGF
may play a role in the angiogenesis of hemangiomas but it is likely not the critical
molecule.211, 214
Vascular Endothelial Growth Factor (VEGF)
Vascular endothelial growth factor is a protein family consisting of with five
splicing products, VEGF-A, -B, -C, -D and placenta growth factor.274 VEGFs mediate
endothelial cell proliferation, migration, survival, cell-cell communication, differentiation
and vessel permeability.275-279 VEGFs bind to three receptor tyrosine kinases: VEGFR-1
(Flt-1), VEGFR-2 (KDR/Flkt-1) and VEGR-3 (Flt-4).274 The critical role of VEGF-A,
VEGFR-1, and VEGFR-2 in development of blood vessels was demonstrated in a study
of knockout mice genetically engineered to be deficient in the VEGFA and VEGFRs
which died of abnormal vasculogenesis.275, 280

60

VEGF and VEGFRs are likely involved in the mechanism of hemangiomas;
however, their exact role remains unclear. VEGF serum concentrations are higher in
patients with hemangiomas compared to patients with malformations and healthy
controls.211 However, no difference in VEGF levels were found in urine excretion
between patients with vascular tumors compared to healthy patients.273 This makes
urinary excretion of VEGF an unlikely candidate for screening or prognostic testing.
Predictably, VEGF staining was greater in proliferating lesions compared to
involuting lesions.214, 259, 281 Hemangiomas stained positively for a number of markers
directly involved in the VEGF/VEGFR pathway.52, 235, 281 The majority of mRNA for
VEGF was localized to pericytes and endothelial cells.211 VEGFR1 was reduced in
hemangioma endothelial cells.244 Consequently, the low VEGFR1 expression resulted in
VEGF-induced activation of VEGFR2 and downstream signaling pathways.244
Correlative, serum levels of VEGFR1 were slightly lower in hemangioma patients
compared to healthy controls and no trend was seen in serum levels of sVEGFR2.282 The
localized manner of hemangiomas may not be sufficient to create a significant change in
the serum levels of these soluble proteins.
VEGF has a number of functions locally and distally. Most hemangioma tissue
cultures are endothelial cells or stem cells by nature; however, stromal cells also play a
role in the mechanism of hemangioma. These stromal cells express VEGF which act as
an autocrine growth factor through the activation of VEGFR-2 as well as a paracrine
factor for endothelial cell growth.283 VEGF can mobilize endothelial progenitor cells
from the bone marrow to sites in need of neovascularization.284 Another VEGF function
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is that it upregulates MMP-9 which is a factor also capable of mobilizing endothelial
progenitor cells and for which there is a positive feedback to VEGF.285
Future treatment ideas may target this extremely angiogenic factor with antisense
VEGF which was successful in hemangioma culture.286
Estrogen
Estrogen acts predominantly through estrogen receptors and is involved in a
number of processes throughout the body including sexual development, fetal
development, coagulation, and cardiovascular repair. The level of circulating estradiol in
the postnatal period is greater than later in life.253 In regard to hemangioma patients, the
level of estrogen in patients with hemangiomas was significantly higher than that of
healthy children.271 Furthermore, the serum level of estrogen and estrogen receptors in
hemangioma tissue was greater in proliferating hemangioma patients when compared to
involuting hemangioma patients.43, 287 This indicates that estrogen may play a role in the
pathogenesis of hemangiomas.
Estrogen may play a regulatory role in regards to key angiogenic factors involved
in hemangiomas. Expression of angiogencic growth factors (bFGF, IGF, TGFb) is
induced by estrogen.16, 43, 288 Furthermore, VEGF, MMP-9 and SDF-1a expression are
also all induced by estrogen.289-292 Estrogen itself can increase angiogenic activity,
mobilize of endothelial progenitor cells and modulate vascular remodeling.293 A
synergistic effect was found with VEGF and estrogen on the angiogenic potential of
cultured hemangioma endothelial cells.294 Estrogen is also protective for hypoxiainduced apoptosis.295-297 Intriguingly, hemangioma cell cultures grew especially well in
hypoxic environments supplemented with estrogen.253, 296, 298 These observations provide
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support for the idea that estrogen may have a critical role in the pathogenesis of
hemangiomas.
Treatment ideas for this regulatory molecule include antiestrogen and estrogen
receptor antagonists.289
Matrix Metallopeptidase-9 (MMP)
Matrix metallopeptidase-9 (MMP), also known as collagenase IV, is an enzyme
involved in the breakdown of extracellular matrix such as degrading type IV collagen and
a number of other matrix proteins.299 The role of MMPs ranges from embryonic
development to tissue remodeling. MMP-9 is inducible in hypoxic environments after
which and mRNA level and enzymatic activity increase by three- to four-fold in tissue.
300-302

MMP-9 is involved in both in angiogenesis and vasculogenesis. MMP-9
mediated release of kit-ligand is necessary for the mobilization of endothelial progenitor
cells from the bone marrow.285, 303-305 Locally, MMP-9 acts by degrading basement
membrane and extracellular matrix which therefore eliminates contact inhibition that
normally blocks endothelial cell proliferation and migration.306 Pathologic involvement
of MMP-9 was identified in angiogenic disease of the retina.285
MMP-9 is expressed in proliferating lesions in addition to VEGF and bFGF.214
High molecular weight MMP was increased in urinary excretion in patients with vascular
tumors compared to healthy controls.273 Furthermore, MMP-9 and VEGFA was
increased in the plasma of proliferating hemangioma patients.282, 285 MMP-9 is likely
within the mechanism pathway of hemangiomas. It is yet to be seen if this can be used as
a prognostic indicator.
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Adipogenesis
Overview
Recent interest in adipogenesis stems from the ever-looming obesity epidemic and
associated complications affecting much of the world. Many researchers are looking at
how to better control adipogenesis and the subsequent physiologic consequences of
excessive fat production. The study of adipogenesis or the differentiation of cells into fat
is fortunately capable of being studied because fat differentiation in vitro is rather similar
to adipogenesis in vivo.307, 308 Almost all work on adipogenesis has utilized either
predetermined clonal cell lines or preadipocytes isolated from stromal-vascular fraction
of dissociated fat pads.307 Knowledge about the differentiation requirements have been
predominately gained through 3T3-L1 and 3T3-F442A, nonconal Swiss 3T3 cells.309, 310
Other cell lines include TA1 311 and Ob1771.312 After treatment with a hormonal cocktail
combination of cAMP, 3-isobutyl-1-methylxanthine, insulin, and glucocorticoids, these
cell lines differentiation over 4 to 8 days.313
Adipocytes are essential for energy homeostasis as well as hemostasis, blood
pressure control, immune function, and angiogenesis. This tissue differs from other types
of tissue because it is dispersed throughout the body at sites of rich loose connective
tissue as well as around the heart, kidney other internal organs. Fat tends to develop in
clusters, in vivo and in vitro; however, the exact mechanism by which recruitment or
differentiation of these clusters is unknown.314 Notably, the earliest event associated with
the development of adipose tissue is a proliferating network of capillaries within
subcutaneous loose tissue.
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In vivo adipocytes originate from multipotent mesenchymal stem cells which are
capapable of also differentiating into osteoblasts and chondrocytes.315 As with most stem
cell lineages, the differentiation process consists of a deterimination and terminal stage.
The differentiation stage is the commitment of the stem cell to the adipocyte lineage and
is accompanied by growth arrest, typically this is acquired through contact inhibition;
however, this is not necessity for adipocyte differentiation.308, 316 Stimulated cells reenter
the cell cycle and progress through at least two cell-cycle divisions termed mitotic clonal
expansion.317-319 Mitosis allows for reorganization of chromatin and production of cellcycle machinery possibly needed to facilitate expression of adipogenic genes.320-322
Second, the terminal differentiation of the pre-adipocyte to a mature adipocyte is when
the cell acquires the necessary specific machinery for lipid synthesis and trafficking,
gains insulin sensitivity and produces adipocyte-specific proteins. 323 This includes
triglyceride accumulation as well as glyerophophotaste dehydrogenase, fatty acid
synthase, acetyl coA carboxylase, GLUT 4, insulin receptor aP2.
A Complicated Transcription Cascade
The exact details of the adipogenic differentiation transcription cascade remains
to be completely elucidated; however, it is understood that differentiation involves a
number of temporally regulated gene-expression events including known transcription
factors, chromatin remodeling, feedback loops, and a number of inhibitory factors. The
most well-known and studied transcription factors are the peroxisome proliferatoractivated receptors (PPARs) and the CCAAT-enhancer-binding proteins (C/EBPs). More
recently, the Kruppel-like factors (KLFs) have been implicated in the regulatory cascade
of adipogenesis. Simply put, dlk is the major inhibitory molecule of adipogenesis in
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concert with Sox9. As dlk and Sox9 levels decrease, C/EBPβ and δ rise transiently and
early during differentiation, followed by the expression of PPARγ within a positive
feedback loop with C/EBPα. These temporally expressed factors ensure commitment and
transcription of adipocyte-specific genes that contribute to the necessary machinery for
mature adipocyte function. Certain KLF factors positively (KLF4, KLF5, KLF6, and
KLF 15) and negatively (KLF2) regulate the aforementioned proteins. These are the
transcription factors that will be of focus in this manuscript in regard to the fattyinvolution of hemangiomas. A summary of the interactions of the discussed adipogenesis
differentiation factors can be seen in Figure 5.
Delta-like kinase (dlk)
Delta-like kinase (dlk also known as Pref-1) is a cellular membrane protein with
unique characteristics. The dlk structure consists of an extracellular six tandem
epidermal growth factor (EGF)-like repeats.324 It also shares structural similarities to the
Notch/Delta/Serrate family, which are involved in cell signaling and cell fate
determination.325 However, dlk lacks a conserved binding domain as with classic Notch
ligands.326 The extracellular domain is cleaved to generate soluable dlk.327 One of the
enzymes found to cleave membrane bound dlk is TNFα converting enzyme (TACE,
ADAM17).328
The interest in dlk in adipogenesis stems from a dramatic decrease in dlk
expression with adipocyte differentiation; it is abundant in preadipocytes. It is not
detectable in mature fat cells.329, 330 It is the only known gene whose expression is
completely down-regulated during adipocyte differentiation. Dlk presence prevents
differentiation, lipid accumulation and expression of adipocyte transcription factors such
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as PPARγ, C/EBPα as well as markers FABp4/aP2.324, 331 It is a commonly used
preadipocyte marker.5, 330, 332-338
Although the specific target of soluable dlk is unknown, it is known that dlk
functions through phosphorylation of ERK in the (mitogen-activated protein kinase) /
(extracellular signal-regulated kinases) MAPK/ERK pathway.331 Dlk, through
MAPK/ERK activation, induces expression of Sox9, a member of the Sox gene family.
Sox9 plays an important role during emrbyogenesis, cellular differentiation, testogenesis,
chodrnogenesis and osteoblastogenesis.324
Sox9 inhibits adipocyte differentiation by directly binding to C/EBPβ and
C/EBPδ gene promotors.331 Similarly to dlk expression, Sox9 expression decreases early
in differentiation.339 This decrease in expression coincides with induction of C/EBPβ and
C/EBPδ. Dlk and Sox9 both promote chondrogenic induction but prevent chondrocyte
maturation, an alternate differentiation pathway.340-343 Both, null and overexpression of
dlk in adipose tissue results in insulin resistance and glucose intolerance.344 This
indicates that these factors are necessary for early differentiation but not sufficient for
proper tissue maturation. Figure 15 illustrates the dlk mechanism of inhibition of
adipogenesis.
In adult tissue, dlk is only found in adipose and certain neuroendocrine tissue,
including pericytes in the blood-brain barrier.345 Dlk, however, is found in multiple
mouse embryonic tissues. Likely, in addition to its role in adipogenesis, dlk also plays a
role in determining mesenchymal stem cell fate.346 Dlk is an imprinted gene.347
In regards to hemangiomas, dlk undergoes a 5-fold decrease on maturation of
hemangiomas.46 This means that the very high levels of dlk expressed by proliferating
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hemangiomas may prevent the formation of fat. Decreasing levels of dlk as the
hemangioma matures releases this inhibition thus promoting fat formation. Given that a
mere 2-fold increase can completely prevent the conversion of preadipocytes to
adipocytes, it is clear that this molecule plays a critical role in the adipogenesis of
hemangiomas.
Peroxisome proliferator-activated receptors (PPARs)
Peroxisome proliferator-activated receptors (PPARs) are a subgroup of the
nuclear receptor superfamily and include PPARα, PPARβ/δ and PPARγ. These nuclear
receptors are ligand-dependent transcription factors that form heterodimers with retinoid
X receptors, see Figure 16.348-352 The DNA binding domain consists of two zinc fingers
that bind to specific peroxisome proliferator response elements (PPREs) found in
enhancer regions. The ligand binding domain is composed of 13 α-helices and a small 4
stranded β sheet.320 The pocket is larger than most other nuclear receptors 353, 354 which
may allow for a broader range of ligand interactions. Known ligands include naturally
occurring fatty acids and their derivatives, eicosanoids, prostaglandins as well as
manufactured antidiabietic agents, thiazolidinediones(TZD).355 Agonist binding leads to
conformational changes in the PPAR structure allowing for recruitment of transcriptional
factors and thus increase in gene expression. The TZDs, a new class of drugs which
increase insulin sensitivity, can directly bind and activate PPARγ and stimulate adipose
conversion.356-358
Each receptor has a unique tissue expression profile. PPARα is expressed in
many metabolically active tissue including liver, kidney, heart, muscle and brown fat.359362

PPARβ/δ is expressed at significant levels in the brain, adipose tissue and skin.360-363
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PPARγ exists in two isoforms created from alternative promoter usage and splicing.
PPARγ1 is found constitutively at low levels throughout the body while PPARγ2 is
expressed in primarily in adipose tissue but also found in fibroblasts and myoblasts.349,
360, 362, 364

PPARγ is critical in a variety of biological processes, including adipogenesis,
glucose metabolism, and inflammation.365 PPARγ2 is the master regulator in adipocyte
differentiation. The presence of PPARγ2 is required for terminal adipocyte differentiation
of embryonic stem cells and fibroblasts in vitro as well as in vivo differentiation.366-369
The expression of ectopic PPARγ is sufficient to induce successful adipocyte
differentiation in nonadipogenic mouse fibroblasts.370 Furthermore, ectopic activation by
PPAR agonist (ETYA) leads to differentiation.370 PPARγ dominant-negative 3T3-L1
cells were unable to differentiation into adipocytes.371, 372 To date, no factor has been
discovered that promotes adipogenesis in the absence of PPARγ.373
Several groups have demonstrated the critical presence that PPARγ plays in
adipocyte differentiation. Heterozygous null mice and dominant-negative PPARγ mouse
models all exhibit reduced or absent amounts of adipose tissue.366, 374,366, 367, 372, 375, 376
Cells in which PPARγ expression was wild or restored exhibit fully functional adipocyte
differentiation capabilities. Mouse models have also shown that lack of PPARγ can lead
to insulin resistance.376, 377
A number of genes are regulated in vivo by PPARγ. The list includes genes
involved in terminal differentiation of adipocytes such as adipocyte fatty acid binding
protein (aP2), phosphoenolpyruvate (PEPCK), acyl-CoA synthetase, LPL, CD36 (cell
surface fatty acid), adipose-specific fatty acid binding protein (FABP4) and FATP1. 349,
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378-381

These genes possess PPREs within their regulator regions. Ligand activation of

PPARγ is required for induction into the adipogenic pathway but is not necessary for
PPARγ-dependent gene expression.377 Interestingly, PPARγ is necessary to maintain
adipocytes in a differentiated state. Mature 3T3 L1 adipocytes transfected with an
adenovirus to dominant-negative PPARγ lead to the de-differentiation of the adipocytes
with loss of lipid accumulation and decrease in adipocyte markers.382
CCAAT-enhancer-binding proteins (C/EBPs)
CCAAT-enhancer-binding proteins (C/EBPs) compile a six member (C/EBPα to
C/EBP ζ) family of basic-leucine zipper transcription factors that promote expression of
genes by acting at CCAAT box motifs present in several gene promoters. These proteins
are found predominately in hepatocytes, adipocytes, hematopoietic cells, spleen, kidney,
and brain. As mentioned above, C/EBPα, C/EBPβ and C/EBPδ have roles in
adipogenesis which have been demonstrated in vivo and in vitro. C/EBPs are important
in adipogenesis but these factors cannot function efficiently in the absence of PPARγ.383
C/EBPα is required for both adipogenesis and normal adipocyte differentiation. It
is induced later in the differentiation process and proceeds most end product genes of
adipocytes likely by inducing the expression of PPARγ. Ectopic expression of C/EBPα
in 3T3-L1 cell lines promotes adipogenesis.322, 384 Furthermore, C/EBPα expression is
necessary to maintaining PPARγ expression in mature adipocytes.385 Similar to C/EBPβ,
ectopic expression of C/EBPα cannot initiate adipogenesis in dominant negative PPARγ
fibroblasts.383
The role of C/EBPα is elucidated in mice models where mice lacking C/EBPα via
replacement of the C/EBPα locus by C/EBPβ show abnormal adipose tissue formation.
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These mice are viable, with normal liver function; however, they have an overall
reduction in the amount of white adipose tissue.382 In dominant negative C/EBPα mice,
those that survive to birth died shortly afterwards due to a lack of gluconeogenesis and
subsequent hypoglycemia; however, restoration of hepatic C/EBPα levels by liverspecific rescue can prevent the lethality of the deletion.386, 387 Expression of exogenous
PPARγ in C/EBPα-deficient cells showed that, C/EBPα is not required for accumulation
of lipid and the expression of many adipocyte genes; however, it is necessary for
acquisition of insulin sensitivity.383, 385, 388
C/EBPβ and C/EBPδ are factors in the adipogenesis cascade but are not the most
critical factors in the adipocyte differentiation. C/EBPβ and C/EBPδ rise early and
transiently during adipogenesis389-391, in part by inducing expression of the adipogenic
transcription factors C/EBPα and PPARγ.373, 392, 393 C/EBP β and δ have direct
transcriptional effect through a binding site in PPARγ promoter.364, 385 Ectopic
expression of C/EBPβ and C/EBPδ in 3T3-L1 preadipocytes promotes adipogenesis in
the absence of extracellular hormones.389-391 C/EBPβ in NIH 3T3 fibroblasts, with and
without C/EBPδ, can induce PPARγ, the key adipocyte transcription factor. These cells
following exposure to PPARγ ligands terminally differentiate into adipocytes.393, 394
However, C/EBPα is not induced in the absence of a PPARγ ligand.322 C/EBPβ
limitation in adipogenesis differentiation is shown by the incapability of adipogenesis in
dominant negative PPARγ cells.395
Nevertheless, C/EBPβ and C/EBPδ are necessary for proper and complete
adipogenic function. Tanaka and colleagues conducted a series of experiments with
C/EBPβ and C/EBPδ knockout mice.392 C/EBPβ knockout mice showed reduced
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adiposity, likely do to decreased lipogenesis not adipogenesis. Furthermore, C/EBPβ and
C/EBPδ double-knockout had even more reduction in adipose-tissue mass. Murine
embryonic fibroblasts from these double-knockout mice show deficiency in C/EBPα and
PPARγ as well as impaired efficiency of adipocyte differentiation in response to
adipogenic extracellular hormone stimuli.392, 396 . However, PPARγ and C/EBPα levels
were normal in the scant adipose tissue. This indicated that there was another, yet less
efficient, transcription cascade capable of regulating adipogenesis independent of the
C/EBP mechanism.392 This was found to be ADD1/SREBP1. Furthermore, it was found
that C/EBPβ cannot induce expression of C/EBPα in the absence of PPARγ because
PPARγ is required to release histone deacytelase-1(HDAC1) from the C/EBPα
promoter.395
Krüppel-like Factors (KLFs)
The Krüppel-like factor family is an important family homologous to the
Drosophila melanogaster embryonic segmentation gene product, Krüppel.397, 398 The
characteristic and highly conserved three Kruppel-like Cys2/His2 zinc-fingers bind at the
C terminus to the CACCC/GC/GT-box,399, 400 found in the regulatory regions of genes,
controlling various biological processes. Similarities in structure create overlap in
transcriptional targets. However, the N terminus is highly variable and is also involved in
gene activation, gene repression, or both, as well as in protein-protein interactions.66
KLF tissue expression is variable while some are expressed ubiquitously (KLF6,
KLF10, KLF11) others are tissue specific (KLF1, erythroid; KLF2, lung; KLF4 and
KLF5, intestines).397 KLFs regulate a broad spectrum of processes including
proliferation, apoptosis, differentiation, development and cell cycle progression401, 402 as
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well as specifics involved in hematopoiesis,403, 404 cardiac remodeling,405 and vascular
biology.406 Alterations in their function have been associated with the pathobiology of
numerous human disease including cardiovascular disease, metabolic disorders, and
cancer.66, 407-409
Reviewed in detail in McConnell and Yang’s 2010 review are the mechanisms of
action of KLFs.66 In summary, KLF actions vary by a number of biochemical
modulations leading to chromatin modifiers, cofactors, and transcriptional machinery.
These modulations vary by group and include: histone aceytyltransferases, CtBP via
histone deactylases (HDACs), and Sin3A via HDAC1 and HDAC2. Posttranslational
modifications needed for KLFs to bind to promoter/enhancer sequences include:
acetylation, phosphorylation, ubiquitiation, and sumolyation. Table 17 provides an
excellent general overview of the function and regulations of all KLFs.
In relation to adipogenesis, the functional CACCC binding sites are found in
the control region of key adipogenic factors, such as C/EBPα and PPARγ.
Subsequently, a handful of KLFs have been identified as critical regulatory molecules in
the transcriptional cascade controlling adipocyte differentiation.407, 409-412 These include:
KLF2, KLF3, KLF4, KLF5, KLF6, KLF7, KLF11, KLF15. From McConnel and Yang,
Figure 5 demonstrates the regulatory effects that KLFs have on during adipogenesis.
KLF2, KLF3, and KLF7 inhibit adipocyte differentiation in part through
inhibition of PPARγ and C/EBPα expression.413-416 Further more, KLF2 promotes a
quiescent phenotype by blocking expression of the growth promoting c-myc.417 KLF11
inhibits adipogenesis more indirectly though cholesterol metabolism pathways.418
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KLF4 and KLF5 promote adipogenesis early in differentiation via transcription
factors C/EBPβ, C/EBPδ and PPARγ.410, 419 Mice lacking KLF4 die shortly after birth
secondary to defects in skin development as the fat layer is disrupted and the barrier
function of the skin is inadequate.420 KLF6 is proadipogenic as it represses the main
inhibitor of adipogenesis, dlk.421 Finally, KLF15 promotes adipocyte differentiation and
is suspected to be activated by early transcription factors, C/EBPβ and C/EBPδ,
subsequently inducing PPARγ, C/EBPα and adipocyte differentiation.422, 423
Also of interest is that KLFs play a regulatory role in cell progression. KLFs can
reprogram somatic cells into inducible pluripotent stem cells and maintain embryonic
stem cells.424-426 Specifically, KLF2, KLF4, and KLF5 work in concert with Nanog to
maintain the self-renewal of the embryonic stem cell.424 More so, KLF4 and KLF5 were
identified as upstream factors in the transcriptional regulatory circuit for somatic cell
reprogramming involving Nanog as well as Pauf5 and Sox2.427, 428
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APPENDIX
Table 1: List of qRT-PCR probes
Purchased from Applied Biosystems (Foster City, CA) as Gene Expression Assays (20x),
also recorded are the associated Unigene, Order Number and Gene Reference Sequence
Number
Target Gene
CEBPA

Unigene
NM_004364

2010 AB#
Hs00269972_s1*

Gene RefSeq#
Hs.699463

CEBPB

NM_005194

Hs00270923_s1*

Hs.517106

CEBPD

NM_005195

Hs00270931_s1*

Hs.440829

DLK1

NM_003836

Hs02574620_s1*

Hs.533717

KLF2

NM_016270

Hs00360439_g1*

Hs.715677

KLF4

NM_004235

Hs00358836_m1*

Hs.376206

KLF5

NM_001730

Hs00156145_m1*

Hs.508234

KLF6

NM_001300

Hs00810569_m1*

Hs.4055

KLF15

NM_014079

Hs00362736_m1*

Hs.272215

PPARG

NM_015869

Hs01115513_m1*

Hs.162646

RXRA

NM_002957

Hs01067640_m1*

Hs.590886

SREBF1

NM_004176

Hs01088691_m1*

Hs.592123

SOX9

NM_000346

Hs00165814_m1*

Hs.647409

NGFR

NM_002507.2

Hs00609976_m1*

Hs.415768

POU5F1

NM_002701

Hs03005111_g1

Hs.249184

SOX2

NM_003106.2

Hs01053049_s1*

Hs.518438

NANOG

NM_024865.2

Hs02387400_g1*

Hs.635882

GAPDH

NM_002046

Hs99999905
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Table 2: List of antibodies for staining and IHC-P and IF results
Listed are the antibodies utilized from AbCam, (Cabridge, MA), the manufacturer
details and summary of staining for both immunohistochemistry (IHC-P) and
immunofluorescence (IF), legend below table.
Protein

AbCam Number

Diagnostic Marker for Hemangioma
GLUT1
ab40084
Stem Cell / Neural Crest
Nestin
ab22035
NG2
ab78284
NGFR
ab78387
Sox2
ab15830
Sox10
ab25978
Pericyte Marker
Calponin
ab46794
DLK
ab21682
SMA
ab7817
Desmin
ab15200
PDGFR-β
ab55571
Endothelial Cell Marker
CD31
ab28364
+
±
Ø

Details
IgG
Clonal

Data
IHC-P
IF

mouse

mono

+

+

mouse
mouse
mouse
rabbit
rabbit

mono
mono
mono
poly
poly

+
Ø
Ø
Ø

+
±
+
-

rabbit
rabbit
mouse
rabbit
mouse

mono
poly
mono
poly
mono

Ø
+
+
-

+
+
+
Ø
-

rabbit

poly

Ø

+

positive staining
weak positive staining
negative staining
staining not done
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Table 4: Descriptive statistics for qRT-PCR relative expression
Descriptive statistics for each of the hemangioma phases for each of the mRNA
probes examined using qRT-PCR ∆∆Ct relative expression compared to HDMEC.
N
SOX2

Proliferative

3

10.73

12.48

7.21

657.30

599.30

346.01

2

425.82

534.52

377.96

12

725.64

1016.41

293.41

Proliferative

3

2477.58

3543.04

2045.57

Early Quiescent

3

896.89

730.07

421.50

Late Quiescent

3

1672.32

1816.25

1048.61

Involuted

2

19534.35

3137.51

2218.56

11

4928.10

7535.69

2272.10

4

2672.87

4400.52

2200.26

Proliferative
Early Quiescent

3

942.07

1444.37

833.91

Late Quiescent

3

1930.14

2845.67

1642.95

Involuted

2

365.96

405.78

286.93

12

1670.00

2825.91

815.77

Proliferative

4

2340.02

3378.05

1689.03

Early Quiescent

3

862.76

1336.71

771.75

Total

Late Quiescent

3

288.40

463.26

267.46

Involuted

2

161.70

140.50

99.35

Total
NGFR

733.58

3

Total

Nanog

1467.16

Std. Error

Late Quiescent
Involuted

Pauf5

1463.00

Std. Deviation

Early Quiescent

Total
SOX9

4

Mean

12

1094.75

2095.72

604.98

Proliferative

4

17985.92

18484.49

9242.25

Early Quiescent

3

18906.35

18513.50

10688.77

Late Quiescent

3

4033.77

6170.50

3562.54

Involuted

2

478.11

556.18

393.28

12

11810.02

15162.34

4376.99

Total
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Continued Table 4: Descriptive statistics for qRT-PCR relative expression

N
DLK

5

4.90E+04

5.32E+04

2.38E+04

2

1.34E+04

5.29E+03

3.74E+03

Late Quiescent

3

2.64E+04

1.34E+04

7.76E+03

Involuted

3

9.93E+04

1.19E+05

6.85E+04

13

4.99E+04

6.56E+04

1.82E+04

4

1.30

1.32

.66

Proliferative
Early Quiescent

3

1.58

2.31

1.33

Late Quiescent

4

1.33

1.05

.53

Involuted

3

.06

.10

.06

14

1.10

1.35

.36

Proliferative

4

298.76

159.50

79.75

Early Quiescent

3

36.63

6.66

3.85

Late Quiescent

3

1034.70

507.95

293.27

Involuted

3

1197.37

1145.62

661.43

13

615.47

716.87

198.82

3

.28

.07

.04

Total
C/EBPβ

Proliferative
Early Quiescent

3

.01

.01

.00

Late Quiescent

3

.22

.13

.08

2

.27

.15

.11

11

.19

.14

.04

Involuted
Total
C/EBPδ

RXR

Proliferative

3

.51

.33

.19

Early Quiescent

3

1.74

1.51

.87

Late Quiescent

2

.64

.13

.09

Involuted

1

.35

.

.

Total

9

.93

.99

.33

Proliferative

5

.43

.32

.14

Early Quiescent

3

.36

.22

.13

Late Quiescent

4

.89

.44

.22

Involuted
Total
SREBF

Std. Error

Early Quiescent

Total
C/EBPα

Std. Deviation

Proliferative

Total
PPARγ

Mean

Proliferative

2

.43

.11

.08

14

.55

.37

.10

5

.33

.32

.14

Early Quiescent

3

.16

.10

.06

Late Quiescent

4

.47

.21

.11

Involuted
Total

2

.15

.11

.08

14

.31

.25

.07
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Continued Table 4: Descriptive statistics for qRT-PCR relative expression
N
KLF2

4

13.89

25.28

12.64

3

19.84

16.13

9.31

Late Quiescent

3

771.20

662.94

382.75

Involuted

3

176.45

68.26

39.41

13

227.54

418.06

115.95

3

43.51

67.18

38.79

Proliferative
Early Quiescent

3

6.99

6.18

3.57

Late Quiescent

3

310.81

260.24

150.25

Involuted

2

69.47

12.00

8.48

11

111.17

177.21

53.43

Proliferative

4

13.73

10.57

5.28

Early Quiescent

3

5.54

7.10

4.10

Late Quiescent

3

78.89

118.58

68.46

Involuted

3

1417.03

2300.04

1327.93

13

350.71

1120.02

310.64

3

8.53

7.10

4.10

Total
KLF6

Proliferative
Early Quiescent

3

47.55

15.64

9.03

Late Quiescent

3

299.94

441.95

255.16

Involuted
Total
KLF15

Std. Error

Early Quiescent

Total
KLF5

Std. Deviation

Proliferative

Total
KLF4

Mean

Proliferative

2

21.85

2.43

1.72

11

101.07

235.95

71.14

3

4.23

6.02

3.47

Early Quiescent

3

8.08

11.23

6.48

Late Quiescent

3

48.79

79.19

45.72

Involuted
Total

3

28.92

15.03

8.68

12

22.50

39.48

11.40
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Table 5: One-way ANOVA
ANOVA results for comparison of multiple hemangioma phases, significant
differences, p<0.05 indicated in bold
Sum of
Squares
SOX2

Between Groups
Within Groups
Total

SOX9

Between Groups
Within Groups
Total

Pauf5

Nanog

Between Groups

DLK

PPARγ

C/EBPα

C/EBPβ

C/EBPδ

RXR

SREBF

3901855.44

Mean Square
3

1300618.48

7462056.77

8

932757.10

11363912.22

11

525252234.23

3

175084078.08

42613757.04

7

6087679.58

567865991.27

10

9216725.36

3

3072241.79
9828313.15

Within Groups

78626505.17

8

Total

87843230.52

11

Between Groups

10056018.47

3

3352006.16

Within Groups

38256256.62

8

4782032.08

48312275.08

11

741875196.23

3

247291732.08
223373495.82

Total
NGFR

df

Between Groups
Within Groups

1786987966.56

8

Total

2528863162.80

11

Between Groups

1.17E+10

3

3.88E+09

Within Groups

3.99E+10

9

4.44E+09

Total

5.16E+10

12

4.32

3

1.44
1.92

Between Groups
Within Groups

19.23

10

Total

23.55

13

Between Groups

2949495.03

3

983165.01

Within Groups

3217340.86

9

357482.32

Total

6166835.89

12

Between Groups

.14

3

.05

Within Groups

.07

7

.01

Total

.21

10

Between Groups

3.04

3

1.01

Within Groups

4.81

5

.96

Total

7.85

8

.66

3

.22

Within Groups

1.09

10

.11

Total

1.76

13

Between Groups

Between Groups

.23

3

.08

Within Groups

.56

10

.06

Total

.79

13

F

Sig.

1.394

.313

28.760

.000

.313

.816

.701

.577

1.107

.401

.875

.489

.749

.547

2.750

.105

4.776

.041

1.051

.447

2.016

.176

1.366

.309
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Continued Table 5: One-way ANOVA

KLF2

Between Groups
Within Groups
Total

KLF4

KLF5

KLF6

KLF15

Sum of
Squares
1206527.54

df

Mean Square
3

402175.85

890724.36

9

98969.37

2097251.90

12

Between Groups

169343.82

3

56447.94

Within Groups

144695.89

7

20670.84

Total

314039.71

10

Between Groups

4444392.94

3

1481464.31

Within Groups

10608962.37

9

1178773.60

Total

15053355.31

12

Between Groups

165480.43

3

55160.14

Within Groups

391229.40

7

55889.91

Total

556709.83

10

3823.64

3

1274.55
1664.75

Between Groups
Within Groups

13318.01

8

Total

17141.65

11

F

Sig.

4.064

.044

2.731

.124

1.257

.346

.987

.452

.766

.545
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Table 6: Tukey post hoc analysis
Post hoc analysis to determine source of significant differences identified with one-way
ANOVA, significant values p<0.05 in bold.
Dependent
Variable
SOX9

(I) Phase
Proliferative

(J) Phase
Early Quiescent
Late Quiescent
Involuted

Early Quiescent

Proliferative
Late Quiescent
Involuted

Late Quiescent

Proliferative
Early Quiescent
Involuted

Involuted

Proliferative

Early Quiescent

Late Quiescent

Involuted

2014.56

.977

2252.35

.001

-1580.68

2014.56

.859

-775.43

2014.56

.979

-18637.45

2252.35

.000

-805.26

2014.56

.977

775.43

2014.56

.979

-17862.03

2252.35

.000

2252.35

.001

*

2252.35

.000

17862.02691

*

2252.35

.000

.27110

*

.08

.047

Early Quiescent
Late Quiescent

.06

.08

.869

Involuted

.01

.09

1.000

*

.08

.047

Late Quiescent

-.21

.08

.126

Involuted

-.27

.09

.080

Proliferative

-.06

.08

.869

Proliferative

-.27110

.21

.08

.126

Involuted

-.06

.09

.922

Proliferative

-.01

.09

1.000

.27

.09

.080

.06

.09

.922

-5.95

240.28

1.000

*

240.28

.048

-162.56

240.28

.903

5.95

240.28

1.000

Late Quiescent

-751.36

256.86

.067

Involuted

-156.61

256.86

.926

*

240.28

.048

Early Quiescent

751.36

256.86

.067

Involuted

594.75

256.86

.165

Proliferative

162.56

240.28

.903

Early Quiescent

156.61

256.86

.926

Late Quiescent

-594.75

256.86

.165

Early Quiescent
Involuted

Late Quiescent

805.26
-17056.77

18637.45247

Late Quiescent
Early Quiescent

.859

Early Quiescent

Late Quiescent
Proliferative

2014.56

*

Early Quiescent
KLF2

1580.68

Sig.

17056.76873

Early Quiescent
Involuted

Std.
Error

Proliferative
Late Quiescent

C/EBPβ

Mean
Difference (I-J)

Proliferative

Proliferative

-757.30873

757.30873
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Figure 15: Dlk mechanism of action
Dlk (shown as Pref-1 in this image) inhibits
adipogenesis. Here the membrane bound
dlk is cleaved by TACE to form soluble dlk.
The target of soluble dlk remains unknown.
Through activating the MEK/ERK pathway
Sox9 expression increases. Sox9 binds the
promoters and inhibits the expression of
C/EBPβ and C/EBPδ. Figure from Sul’s
minireview on dlk.324

Figure 16: PPARγ Binding Motif and Cofactors
Illustration of necessary binding
for terminal genes to form mature
adipocyte. Image from Choi’s
review of Artepellin and PPARγ 429
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Figure 17: Review of Krϋppel-like Factor Functions
From McConnell and Yang’s 2010 review on KLFs66
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Continued Figure 17: Review of Krϋppel-like Factor Functions
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